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Abstract
Consensus is lacking on early diagnostic criteria and the exact symptoms of Alzheimer’s
disease (AD). A new, in-office test may help physicians detect the early symptoms of
AD, based upon new National Institute of Aging (NIA) criteria. However, a gap exists in
knowledge regarding physicians’ current use or intent to use the new protocols.
Choreographing the descriptive AD terminology in the Diagnostic and Statistical Manual
of Mental Disorders IV-TR and the International Classification of Diseases (ICD-10) is
recommended. Thus, the purpose of this study was to understand possible contributing
factors to physician's use or intent to use of the new NIA's diagnostic protocol. Data
collected from 55 clinicians within 2 Northern California counties were analyzed using a
bivariate test. The 2 dependent variables were physicians’ use of, or intent to use, the
NIA protocol; the 6 independent variables were number of years since graduating from
medical school, area of specialty, percentage of patients over age 60 years, physician's
gender, age, and knowledge about AD, as indicated by performance on the Alzheimer’s
Disease Knowledge Scale. The results of regression analyses indicated no statistical
significant associations between the variables of interest (p ≥ .05). This study is a first
attempt at understanding physician attitudes toward, and usage patterns of, an important
new in-office tool for early detection of AD. Further research using a larger sample size
to increase power is needed. These findings have implications for positive social change
by promoting an earlier detection of Alzheimer's disease, underscoring the need for
additional training, and revising the terminology used in clinicians’ desktop references.
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Chapter 1: Introduction to the Study
Introduction
Dementia of the Alzheimer’s disease (AD) type is reaching epidemic proportions
globally Lindesay et al. (2010). Awareness of AD, early recognition of AD, and
increased research on this type of dementia are causing this life-changing disease to rise
as a significant concern and a healthcare priority Lindesay et al. (2010). Lindesay et al.
(2010) reported that some physicians still use the term senile dementia, which contributes
to the fallacy that dementia is a natural progression that comes with age. AD is not a
normal part of aging. Researchers have identified a need to improve general practitioners’
and primary care providers’ skills in diagnosing AD patients, early diagnosis of
dementia/AD, and referrals for additional evaluation of patients’ symptoms (Lindesay et
al., 2010; Schoenmakers, Buntinx, & Delepeleire, 2009).
There is a gap in knowledge regarding physicians’ knowledge and use of the
National Institute of Aging (NIA) criteria for all-cause dementia. Diagnostic tests within
the office for the early detection of AD, such as the NIA criteria, are needed for the
accurate diagnosis of early AD. These new criteria are described and discussed in
Chapter 2. The purpose of this study was to explore the correlations between physicians’
background characteristics and knowledge of AD and their intention to adopt or not to
adopt the new criteria.
Chapter 1 includes a brief introduction, review of background to the research
subject, discussion of the problem statement, purpose of the study, identifying the
research questions and hypotheses, theoretical framework for the study, nature of the
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study, definitions, assumptions, scope, delimitations, limitations and the significance of
the research.
Background
Leifer (2009) reported that patients and/or family members caring for loved ones
who exhibit symptoms suggestive of AD tend to seek help initially from their primary
care physicians (PCPs). PCPs must be aware of AD symptoms and should screen aging
patients for AD. In Leifer’s study, family doctors (73%) and internists (11%) were the
first physicians consulted regarding the concern about AD. After reporting symptoms to
their family doctors, 62% of patients with AD remained undiagnosed (Leifer, 2009).
AD is expected to become more prevalent as the elderly population in the United
States increases. By the year 2040, more than 80 million individuals in the United States
will be affected by AD (Forlenza, Diniz, & Gattaz, 2010; Leifer, 2009). A meta-analysis
conducted in 2009 indicated the approximate prevalence of AD in the United States
increased 1% at 65 - 69 years of age to 13 - 17% at 85 - 89 years of age and 24 - 31% at
90 - 94 years of age (Leifer, 2009).
Healthcare providers use AD as a diagnostic term or way of labeling or even
attaching a disease term to patients and AD is only one of many forms of dementia
(Bassil & Grossberg, 2009). (The other terminology and use of forms for AD are
discussed in Chapter 2.) According to Jack et al. (2011), widely used criteria for the
clinical diagnosis of AD were established in 1984 by the National Institute of
Neurological Disorders and Stroke (NINDS) and the Alzheimer’s disease and Related
Disorders Association (ADRDA). Since the development of the NINDS and ADRDA
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criteria, there have been many advances in AD research, which have led to new
diagnostic techniques and thus to three stages for the classification of AD (Jack et al.,
2011). These improvements in diagnostic testing, and a better understanding of
pathology, have generated greater understanding of AD than is reflected in the NINDS
and ADRDA criteria (Jack et al., 2011).
Over the past quarter century, various tests such as use of imaging equipment
have been used to detect AD. Research is ongoing concerning imaging techniques and the
use of biomarkers to detect AD at the earliest stage possible. Psychological testing has
been accomplished through various tests as well as memory recall evaluations. The
evaluation of the patient’s medical history remains a central part of the AD evaluation
process.
Yet, according to Jack et al. (2011), recent studies indicated that the early
detection of AD does not require expensive imaging equipment or other equipment that
evaluates cognitive domains beyond memory recall. If, formal cognitive testing of AD is
not feasible, then cognitive functions can still be assessed through an in office test. For
example, the clinician can ask the patient to learn an address during the interview and
then ask the patient to recall the address a few minutes later. Or the clinician can ask the
patient to name four items (e.g., a notepad, a stapler, a telephone, and a pen), place them
in various locations around the room, and later ask the patient to recall the location of the
items and their names. Additionally, Mini-Cog state exams and computer programs such
as the Computer-Administered Neuropsychological Screen for Mild Cognitive
Impairment (CANS-MCI), a self-administered touch-screen battery, may be used to
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evaluate patients for AD Jack et al. (2011). These examples are in office exams for early
detection of AD and may lead to other healthcare tests authorized by the provider when
assessing a patient using the new NIA AD criteria.
The new NIA AD criteria may be used to detect AD in the early stages of the
disease process. Central to these new evaluation criteria are (a) a history taking from
both the patient and a knowledgeable informant, and (b) an objective cognitive
assessment, which takes the form of either a bedside mental status exam (see the previous
paragraph for an example) or neuropsychological testing and a combination of two or
more cognitive or behavioral criteria Jack et al. (2011). What is not known is how
providers’ might adapt their knowledge, attitudes, and behaviors (KAB) to the new NIA
AD diagnostic criteria (Aday & Cornelius, 2006).
Upon a noticeable decline in cognitive function and performance can not be
reasonably explained by a known disorder, then a neuropsychological test is indicated
after an examination of patient history and mental status cannot provide a diagnosis and
suspicion of cognitive impairment is detected Jack et al. (2011). The cognitive or
behavioral impairment of two or more domains constitute a diagnosis of all-cause
dementia: Core clinical criteria. There are five domains which frame a diagnosis of AD
and include: impaired ability to acquire and remember new information, impaired
reasoning and handling of complex tasks, impaired visuospatial abilities, impaired
language functions, and changes in personality from which two or more are indications of
AD Jack et al. (2011).
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Problem Statement
There is no consensus on the exact symptoms of AD that GPs can use to diagnose
early, middle, and late stage AD in their patients. Research indicated that as of yet, no
studies have been conducted to explore physicians’ use or willingness to use the new NIA
AD criteria (Jack et al., 2011).
In this quantitative study, I put forth the hypothesis that few physicians are aware
of the new NIA diagnostic criteria for AD, and those who are aware may or may not use
them. Inconsistencies and gaps in the literature over the past 8 years identify gaps in
physicians’ accurate recognition of the early signs and symptoms of AD, misuse of the
phrase Alzheimer’s disease to describe a condition in a living person (literature indicates
that a diagnosis of AD is conducted at autopsy and discussed further in Chapter 2). Use
of the new NIA criteria may help physicians detect the early signs of AD to align
treatment plans more accurately and quickly to address the patients’ level of needs.
While the NIA AD protocol has not been evaluated by clinicians (Jack et al.,
2011), researchers and clinicians have agreed that a test (e.g., the NIA protocol) is needed
to detect the early symptoms of AD and should be used by healthcare providers as an
effective means of detecting AD in early stages (Christensen & Lin, 2007). In this study,
I will explore correlations between (a) physicians’ background characteristics and
knowledge of AD and (b) their use of, intention to use, or intention not to use the NIA
criteria.
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The results of this study has the potential for effecting social change by providing
physicians’ a means for early detection of AD in an office setting and streamlining
treatment plans to precisely address patients’ level of needs. In other words, patients
could receive earlier access to healthcare options for treating their symptoms and
activation of insurance benefits for the treatment of AD symptoms. The way AD is
diagnosed today physicians’ depend on the Mini-Cog state exam and similar tests to
evaluate cognitive status. Nevertheless, that may cause the disease to be underreported
and misdiagnosed. The U.S. Preventive Services Task Force (USPSTF)) found
insufficient data to recommend for or against routine screening for dementia in those
aged 65 and over (Boustani, Peterson, Harris, & Lohr, 2003).
The results of this study may also advance current knowledge of the new
diagnostic criteria for AD. It may advance physicians’ knowledge of AD, earlier
diagnosis of AD and treatments of associated symptoms, and identify the exact criteria
doctors use to diagnose patients presenting with AD symptoms, and possibly change their
attitude toward using the new NIA early detection criteria. The discussion in Chapter 2
will address the importance of early detection of AD and the need to use the NIA criteria.
Purpose of the Study
In January 2010, President Obama endorsed the National Alzheimer’s Project
Act. The Act is focused on improving AD research and services at all levels, as well as
accelerating treatments to abate AD. The purpose of this research investigated
physicians’ use of the NIA protocol through a set of two primary research questions on
the relationship between various physician background characteristics and their use of,
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intention to use, or intention not to use the NIA criteria for all-cause dementia and the
early detection of Alzheimer’s disease. The data collected will be useful for descriptive
and inferential statistical analysis to then examine the data, which may or may not
authenticate the study’s hypotheses.
The independent variables in this study were the number of years since graduating
from medical school, area of specialty, percentage of patients over age 60 years,
physician gender, physician age, and knowledge about AD, as indicated by performance
on the Alzheimer’s Disease Knowledge Scale (ADKS). In this study, there were three
dependent variables (represented by the three primary research questions): use of the NIA
protocol, intention to use the NIA protocol, and intention not to use the NIA protocol.
The research questions described in this chapter and Chapter 3 may identify correlations,
which will be discussed further in Chapters 4 and 5.
Research Questions and Hypotheses
The identified gaps are represented as three dependent variables and in turn
represent two main research questions and hypotheses. Each main research question has
six subquestions that relate directly to the independent variables in this study and that
correspond to the survey instrument. The two primary research questions and associated
subquestions are as follows:
Research Question 1: Are a physician’s background characteristics and
knowledge associated with the physician’s use of the National Institute on Aging
(NIA) criteria for the detection of Alzheimer’s disease (AD)?
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Subquestion 1A: Is the number of years since a physician graduated from medical
school associated with that physician’s use of the NIA criteria for the detection of
AD?
H0A: The number of years since a physician graduated from medical
school is not associated with that physician’s use of the NIA criteria for
the detection of AD.
Ha1A: The number of years since a physician graduated from medical
school is associated with that physician’s use of the NIA criteria for the
detection of AD.
Subquestion 1B: Is a physician’s area of specialty associated with that physician’s
use of the NIA criteria for the detection of AD?
H01B: A physician’s area of specialty is not associated with that
physician’s use of the NIA criteria for the detection of AD.
Ha1B: A physician’s area of specialty is associated with that physician’s
use of the NIA criteria for the detection of AD.
Subquestion 1C: Is the percentage of patients over the age of 60 years in a
physician’s practice associated with that physician’s use of the NIA criteria for
the detection of AD?
H01C: The percentage of patients over the age of 60 years in a physician’s
practice is not associated with that physician’s use of the NIA criteria for
the detection of AD.
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Ha1C: The percentage of patients over the age of 60 years in a physician’s
practice is associated with that physician’s use of the NIA criteria for the
detection of AD.
Subquestion 1D: Is a physician’s gender associated with that physician’s use of
the NIA criteria for the detection of AD?
H01D: A physician’s gender is not associated with that physician’s use of
the NIA criteria for the detection of AD.
Ha1D: A physician’s gender is associated with that physician’s use of the
NIA criteria for the detection of AD.
Subquestion 1E: Is a physician’s age associated with that physician’s use of the
NIA criteria for the detection of AD?
H01E: A physician’s age is not associated with that physician’s use of the
NIA criteria for the detection of AD.
Ha1E: A physician’s age is associated with that physician’s use of the NIA
criteria for the detection of AD.
Subquestion 1F: Is a physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, associated with that
physician’s use of the NIA criteria for the detection of AD?
H01F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is not
associated with the physician’s use of the NIA criteria for the detection of
AD.
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Ha1F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is associated
with the physician’s use of the NIA criteria for the detection of AD.
Research Question 2: Are a physician’s background characteristics and knowledge
associated with the physician’s intention to use the National Institute on Aging (NIA)
criteria for the detection of Alzheimer’s disease (AD)?
Subquestion 2A: Is the number of years since a physician graduated from medical
school associated with that physician’s intention to use the NIA criteria for the
detection of AD?
H02A: The number of years since a physician graduated from medical
school is not associated with that physician’s intention to use the NIA
criteria for the detection of AD.
Ha2A: The number of years since a physician graduated from medical
school is associated with that physician’s intention to use the NIA criteria
for the detection of AD.
Subquestion 2B: Is a physician’s area of specialty associated with that physician’s
intention to use the NIA criteria for the detection of AD?
H02B: A physician’s area of specialty is not associated with that
physician’s intention to use the NIA criteria for the detection of AD.
Ha2B: A physician’s area of specialty is associated with that physician’s
intention to use the NIA criteria for the detection of AD.
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Subquestion 2C: Is the percentage of patients over the age of 60 years in a
physician’s practice associated with that physician’s intention to use the NIA
criteria for the detection of AD?
H02C: The percentage of patients over the age of 60 years in a physician’s
practice is not associated with that physician’s intention to use the NIA
criteria for the detection of AD.
Ha2C: The percentage of patients over the age of 60 years in a physician’s
practice is associated with that physician’s intention to use the NIA
criteria for the detection of AD.
Subquestion 2D: Is a physician’s gender associated with that physician’s intention
to use the NIA criteria for the detection of AD?
H02D: A physician’s gender is not associated with that physician’s
intention to use the NIA criteria for the detection of AD.
Ha2D: A physician’s gender is associated with that physician’s intention to
use the NIA criteria for the detection of AD.
Subquestion 2E: Is a physician’s age associated with that physician’s intention to
use the NIA criteria for the detection of AD?
H02E: A physician’s age is not associated with that physician’s intention
to use the NIA criteria for the detection of AD.
Ha2E: A physician’s age is associated with that physician’s intention to
use the NIA criteria for the detection of AD.
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Subquestion 2F: Is a physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, associated with that
physician’s intention to use the NIA criteria for the detection of AD?
H02F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is not
associated with the physician’s intention to use the NIA criteria for the
detection of AD.
Ha2F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is associated
with the physician’s intention to use the NIA criteria for the detection of
AD.
Theoretical Framework for the Study
Rogers’s (2003) diffusion of innovations (DOI) theory was chosen as the
theoretical framework for this study because historically, his theory has been used to
better understand the dissemination and implementation of interventions specifically
within the healthcare community such as interventions for autism, HIV/AIDS, substance
abuse, and conduct disorder (Dingfelder & Mandell, 2010). Rogers’s DOI theory
concentrates on describing how, why, and at what rate new technologies spread through
social systems (Dingfelder & Mandell, 2010). The diffusion of innovation is the process
by which a new practice or idea is vetted over time with collaborative members of a
social system (Rogers, 1995, 2003).
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The survey instrument explored three dependent variables exploring knowledge,
attitudes, and behaviors (KAB) (KAB; Aday & Cornelius, 2006). The KAB theoretical
approach may help explain data and responses, for example, when a respondent selects
either an “other” response or adds a narrative response in the survey instrument then the
response may fit into one of the three categories of knowledge, attitudes, or behaviors
(Aday & Cornelius, 2006). A detailed explanation of Roger’s (2003) Diffusion of
Innovations (DOI) theory and the theoretical application of both DOI and KAB to this
research are presented in Chapter 2. A discussion of the application of DOI theory and
KAB survey design to this study is discussed in Chapter 2.
In Figure 1, I adapted a figure from a study that explored the implementation of
an autism intervention within the DOI framework (Dingfelder & Mandell, 2011). This
study’s use of the DOI theory is similar to mine, and I see the NIA protocol as analogous
to the autism intervention. Figure 1 is an illustration of DOI theory as it was used in this
study to explore how an innovation or new idea—in this case, implementing the new NIA
criteria for all-cause dementia and early detection of AD—might be perceived by
physicians/clinicians. DOI theory is well suited for exploring physicians’ knowledge and
use patterns related to the NIA criteria for all-cause dementia and early detection of AD
because it offers a logical approach to implement the use of changes in healthcare, i.e.,
breast cancer treatment and procedures for implementing new procedures as discussed in
Chapter 2.
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Dissemination
(New NIA Early
detection of AD criteria)

Adoption

Implementation

Maintenance

Key Terms:
1.
2.

3.
4.
5.
6.

Innovation: an idea, practice or object that is perceived as new by an individual or
organization.
Innovation-decision process: the process by which an individual or organization passes
from (1) initial awareness of an innovation to forming attitudes about and deciding to
adopt or reject the innovation, to implement and preliminary use, to consistent and
committed use.
Dissemination: targeted strategies to make potential adopters aware of an innovation
and encouraged to adopt it.
Adoption: commitment to begin using the innovation.
Implementation: when an individual or organization puts an innovation to use.
Maintenance: the degree to which an innovation in continued over time, particularly
after attempts to diffuse the innovation end (Also known as “sustainability”).

Figure 1. DOI theory applied to the NIA criteria. Modification of figure from “Bridging
the Research-to-Practice Gap in Autism Intervention: An Application of Diffusion of
Innovation Theory,” by H. Dingfelder and D. Mandell, 2011, Journal of Autism &
Developmental Disorders, 41(5), 597-609. doi:10.1007/s10803-010-1081-0

15
Nature of the Study
The study was a quantitative, cross-sectional survey designed to examine
physicians’ use patterns of the NIA criteria for all-cause dementia and the detection of
AD. Via an online survey instrument, I gathered data from physicians responsible for
evaluating patients with signs of AD. The survey instrument contained items designed to
collect data related to the three primary research questions (RQs) and associated
subquestions based on KAB theory. The third research question was ultimately removed
the purpose for removing the third RQ is discussed in Chapter 4. The three dependent
variables (a) current use of the NIA protocol, (b) intention to use the NIA protocol, and
(c) intention not to use the NIA protocol). Again, (c) representing the third research
question was removed as the question and results were the inverse of RQ 2 or (b). The
six independent variables (years since graduating from medical school, area of specialty,
percentage of patients age 60 years and older, physician age, physician gender, and
knowledge of AD). The six independent variables may or may not have any noticeable
relationship to use of (or intention to use/not use) the NIA protocol, but were considered
for the purpose of exploring potential correlations to the dependent variables. Results
from the survey instrument were expressed as percentages; descriptive and inferential
analyses of the data are discussed in Chapter 3 and Chapter 4.
Data was collected from qualified, voluntary, respondents via the survey
instrument. The data was statistically analyzed via the odds ratio, chi square, and P value
procedures. The data analysis plan and procedures are detailed in Chapter 3.
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Definitions
Alzheimer’s disease (AD): A terminal disease without known etiology, treatment,
or cure, causing significant decline of cognitive skills, psychomotor skills, and primarily
affecting those age 65 years old and older (Forlenza et al., 2010).
Amyloid beta (Abeta): A neurotoxic neuron that negatively affects brain tissue;
widely accepted as the main biologic suspect in AD, causing early onset memory loss
and/or death (Tiedeman et al., 2011).
All-cause dementia: Cognitive or behavioral impairment that involves a minimum
of two domains, such as impaired ability to acquire and remember new information,
impaired reasoning and handling of complex tasks, impaired visuospatial abilities,
impaired language functions, and/or changes in personality (Frantz, 2011).
Classical Alzheimer’s disease symptoms (CADS): The preclinical stage wherein
the person demonstrates frequent memory loss (e.g., poor recognition of immediate
family members, loss of appetite, lack of interest in social activities). A condition of a
person alive with a combination of documented signs found in current literature
describing dementia such as lack/loss of memory, loss of cognitive skills, as well as
decreased psychomotor skills, and demonstrating early stages of what current literature
describes as AD. Unlike what has also been referenced in some literature in specific
reference to patients currently diagnosed with AD to describe the cause of death also
described as preclinical AD by the Alzheimer’s Association (Frantz, 2011).
General practitioner (GP): A licensed medical doctor who may have limited
training to use current diagnostic tests to assess a patient presenting dementia or AD
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symptoms, unlike a gerontologist (Schoenmakers et al., 2009).
International Classification of Diseases (ICD): ICD-10 was endorsed by the 43rd
World Health Assembly in May 1990 and came into use in World Health Organization
(WHO) Member States in 1994. The classification is the latest in a series that has its
origins in the 1850s. The International Statistical Institute adopted the first edition,
known as the International List of Causes of Death, in 1893. WHO took over the
responsibility for the ICD at its creation in 1948 when the Sixth Revision was published
and included causes of morbidity for the first time. The World Health Assembly adopted
WHO Nomenclature Regulations in 1967 that stipulate the use of ICD in its most current
revision for mortality and morbidity statistics by all Member States (Centers for Medicare
& Medicaid Services [CMS], 2012).
Knowledge, attitudes, and behaviors (KAB) theory: KAB theory is a research
style that has been used to explore respondents’ knowledge, attitudes, and behaviors that
may lead to an outcome. Knowledge will be measured by right and wrong answers from
Part 2 of the survey instrument, which will explore respondents’ knowledge of AD
through the 30-question Alzheimer’s Disease Knowledge Test (Carpenter et al., 2008).
Physicians’ attitudes will be assessed through the survey instrument, which will gauge
their intent to either use or not use the NIA protocol. The examination of beliefs is
beyond the scope of the current research, but future researchers investigating NIA
protocol use could examine specific aspects of physicians’ beliefs. A more detailed
illustration is seen in Table 7 in Chapter 3, in which KAB theory is aligned to
measurement, assessment, and references (Aday & Cornelius, 2006).
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Magnetic resonance imaging (MRI): A type of medical imaging that uses the
characteristic behavior of protons when placed in powerful magnetic fields to make
images of tissues and organs. Certain atomic nuclei with an odd number of neutrons,
protons, or both are subjected to a radiofrequency pulses, causing them to absorb and
release energy. The resulting current passes through a radiofrequency receiver and is then
transformed into an image. This technique is valuable in providing soft-tissue images of
the central nervous and musculoskeletal systems. Imaging techniques allow visualization
of the vascular system without the use of contrast agents. Agents such as gadolinium are
available for contrast enhancement but must be used with caution in patients with renal
insufficiency (Davis, 2009).
Mild cognitive impairment (MCI): A subjectively sensed, and objectively
verifiable, loss of memory that may result in difficulties with word finding, naming, or
complex skill execution; it does not generally impair a person's ability to carry out
normal activities of daily living. Mild cognitive impairment is also known as cognitive
impairment, not dementia (CIND), and age-associated memory impairment (Davis,
2009).
National Institute of Aging (NIA) criteria: New criteria for diagnosis of dementia
due to AD. A workgroup in partnership with the National Institute on Aging and the
Alzheimer’s Association published new criteria for the diagnosis of dementia due to AD.
The workgroup developed three categories: (a) probable AD dementia, (b) possible AD
dementia, and (c) probable or possible AD dementia with evidence of AD
pathophysiological process (McKhann et al., 2011).
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Neurofibrillary tangles (NFTs): Linked to AD and memory loss, cognitive
function, and ability to care for oneself in the final stage of AD. The tangles may appear
as mushy grey matter and are widely seen in postmortem exams of patients with
suspected AD (Snowdon, 2003).
Neuropil threads (NTs): A mixture of proteins that may be related to diseases
related to aging including AD. Neuropil threads are composed of tau and Ab-amyloid
proteins. The cellular composition of neurofibrillary tangles (NFTs) and neuropil threads
make up the altered tau protein, while extracellular amyloid plaques consist of strings of
Ab-peptide (Ferreira & Bigio, 2011).
Primary care providers (PCPs): Nurse practitioners, physician’s assistants, and
medical doctors that initially evaluate and provide healthcare for patients (Leifer, 2009).
Quantitative MRI (qMRI): A type of tomography imaging used in a medical
setting using powerful magnetic fields to create images of the body. The images produced
assist in the evaluation of organs and the supporting structures of the skeleton without the
use of contrast agents employed in other imaging techniques. Quantitative MRI has
demonstrated robust statistical confidence in limited populations of AD patients,
promoting the advancement of further studies using similar technology in the evaluation
of AD (Fearing et al., 2007).
Type of practice (TOP): Internal medicine, family medicine, osteopath, general
practitioner, and nurse practitioner are types of medical practices that may encounter
patients aged 60 and older (Wenger et al., 2009). I will not evaluate nurse practitioners,
as they are outside the scope of this research.

20
World Health Organization (WHO): The World Health Organization is a global
organization independently renowned for overseeing issues relating to health, guiding
healthcare, establishing policies, monitoring health on a global level, and advising policy
makers (WHO, 2012).
Assumptions
The study population was composed of physicians in Modesto, California. The
estimated minimum sample size will be 97 physicians in order to conduct the bivariate
and multivariate analysis. The population of physicians in Modesto was assumed similar
in terms of diversity, socioeconomic status, and education to the population of physicians
in other cities and towns in California. The study population was assumed to be treating
populations similar to those treated by doctors in other cities and towns in California. The
city of Modesto is within a 100-mile radius of larger cities located in Northern California
such as San Francisco, Oakland, Sacramento, Fresno, and San Jose. The population for
this study will be assumed to be reflective of cities within this radius, which are similar to
Modesto in terms of healthcare, socioeconomic factors, education, culture, diversity,
employment, and age distribution based on types of home, home values, opportunities for
K-12 education and higher education, and access to healthcare facilities.
Slightly more than sixteen surveys were considered successfully completed and
enough data was gathered to evaluate the research questions. The significance of sixteen
completed surveys correlates to statistical model predicted as being statistically
significant per the G*Power output needed for evaluating the smallest sample size. My
goal is to achieve an 80% or greater response rate from the survey instrument and
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discussed in Chapter 4. I assumed that study subjects answered the survey in a frank and
honest manner. I further assumed that data collected helped better explain the results in
Chapter 4 as they may relate to both the DOI and KAB research theories.
Scope and Delimitations
To date, there are no other studies, which evaluated the predictors for physicians’
use of the new NIA Alzheimer’s assessment protocol for the early detection of AD. An
aim of this study was to magnify the need to assess and detect the early signs of AD.
Literature such as the ICD-10, DSM-IV, and some professional journals do not align with
the NIA or with researchers who have stated that AD is 100% identifiable under a
microscope. Presently, patients are diagnosed by their doctors with a disease and labeled
as Alzheimer’s patients.
This study will not directly involve patients. The inclusion of age and sex of the
provider on the survey may lead to a correlation suggesting a particular age or sex of a
practitioner who may or may not use the new protocol, as well as other relevant
covariates, as illustrated in Table 1 below and discussed further in Chapter 3. For
evaluating respondents’ level of knowledge, respondents will be scored on number of
right and wrong answers from the ADKT consisting of 30 questions. The level of
attitudes was evaluated via the three dependent variables. The level of behaviors was also
be assessed through responses related to the three dependent variables.
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Table 1
Covariate Variables
Subquestions
for RQs 1-3

A
Independent
variable
(IV)
explored:
Years since
graduating
from
medical
school

B
Independent
variable (IV)
explored:
Physicians’ area
of specialty

C
Independent
variable
(IV)
explored:
Percentage
of patients
aged 60 and
older

D
Independent
variable (IV)
explored:
Physicians’
Age

E
Independent
variable (IV)
explored:
Physicians’
gender

F
Independent
variable (IV)
explored:
Knowledge of
AD

Note. Research theory used = DOI; evaluation methodology = KAB; data source =
Schultz survey; level of measurement = bivariate; analysis procedures: Pearson’s or chi
square.
Limitations
A convenience sampling strategy was selected for this research. It was intended
that volunteers were reflective of other physicians in Modesto, California. Convenience
sampling was selected because the sample will be taken from one geographic area. I am
aware that findings from this study may not reflect other states and localities, as
demographic factors may skew data in some unknown manner.
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Significance
The U.S. National Institute on Aging ranked AD as the sixth most deadly disease in
the U.S. (Tiedeman et al., 2011). The benefits of early detection and accurate diagnosis of
AD, like many other diseases, include improved disease management and quality of life.
This study may lead to social change by promoting awareness of the importance of early
AD diagnosis. Accurate diagnosis may assist families in reviewing finances, legal
planning, discussing home care and long-term care alternatives, and evaluating safety
practices (Leifer, 2009). This study may promote social change by encouraging
providers to (a) implement routine procedures for the detection of possible dementia in
primary care offices and clinics, (b) begin early diagnostic evaluations for persons
suspected of exhibiting AD symptoms, and (c) partner with those who are likeminded to
provide care planning at the earliest possible time following a diagnosis, and (d)
document the diagnosis and care plan in a person’s medical record (Attea & Johns, 2010).
In 2010, the National Institutes of Health (NIH) announced the blueprint for the
Neuroscience Research Initiative on the Human Connectome Project to share information
about the structural and functional connectivity of the healthy brain using state-of-the-art
imaging instruments, analysis instruments, and information technologies to map human
brain function. The data from this study are expected to help develop a foundation to
advance knowledge of how the brain changes with age and AD. This new information
may change how providers evaluate, treat, and care for elderly patients with advancing
stages of dementia leading to AD McNab et al. (2013).
This study may promote the use of the NIA criteria to detect early signs of AD and
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to promulgate NIA’s recommendations as a new gold standard. On a global scale, the
early detection of AD may affect social change by directly improving the lives of those
with AD and their caregivers.
Summary
AD of the dementia type has reached the level of an epidemic. The purpose of this
study was to explore each of the two dependent variables through a series of research
questions and related narrative fields (which will not be directly evaluated but may be
helpful in explaining the data in Chapter 4) by exploring participants’ knowledge,
attitudes, knowledge, and patterns using the NIA criteria for all-cause dementia and the
early detection of AD.
Chapter 2 will identify gaps between physicians’ current use, intent to use, or
intent not to use the NIA AD protocol (the dependent variables) through a series of three
research questions and related narrative fields (which will not be directly evaluated but
may be helpful in explaining the data in Chapter 4). In addition, in Chapter 2 a detailed
review of relevant AD studies using DOI theory, KAB survey quantitative methods, and
an in depth literature on the research topic presented. Next, in Chapter 3 a description of
the research methodology that was used to frame statistical models, the pilot study and
data collection process is presented. In Chapter 4 the results of the pilot study were
presented as well as the discussion of the characteristics of the sample population was
discussed. A comprehensive statistical analysis of the data also covered. The final
chapter, Chapter 5 discloses the interpretation of the data collected from Chapter 4 and
possible implications for Social Change wrap up the final chapter.
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Chapter 2: Literature Review
Introduction
As Baby Boomers age, an estimated 11–16 million seniors in the United States of
America will have some form of AD (Okie, 2011). Thus, there is a need for early AD
dementia diagnosis, and the new NIA AD diagnostic protocol needs to be explored to
assess if physicians are using the protocols or not. A workgroup in partnership with the
NIA and the Alzheimer’s Association published new criteria for the diagnosis of
dementia due to AD (McKhann et al., 2011). The workgroup developed three categories:
(a) probable AD dementia, (b) possible AD dementia, and (c) probable or possible AD
dementia with evidence of AD pathophysiological process. The first two are intended for
all clinical settings, while the third was established for research purposes only (McKhann
et al., 2011). The following discussion will outline the need for this study.
The expense for treating current patients with AD in 2011 was reportedly $130
billion and may top $1 trillion by 2050 in Medicare and Medicaid expenses. Comparably,
approximately 10% of seniors between the age of 70 and older have dementia (Okie,
2011). The significance of the growing population in terms of sheer numbers, incidence
of AD, and expense for treating the disease by providing patients with various levels of
activities of daily living is illustrated in Figure 2. Seniors with AD may lose their higher
level of function requiring assistance with activities of daily living such as bathing,
toileting, eating, dressing, and administration of medications.

Proportion of Caregivers of People with Alzheimer’s and Other Dementias
vs. Caregivers of Other Older People Who Provide Help with Specific Activities
of Daily Living, United States, 2009
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Figure 2. Modification of a graph adapted from Alzheimer’s Association, (2012c). 2012
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diagnosis of AD through laws passed by President Obama known as the Affordable Care
Act. The Affordable Care Act falls inline with the new NIA AD diagnostic criteria
suggesting doctors should inform their patients of the diagnosis, seeing the benefit of at
last knowing what has been causing the patient2012
problems.
TheFactslack
of communication
Ó
Alzheimer’s Disease
and Figures
Caregiving
from the GP to the caregiver’s family was previously identified as an obstacle to
satisfaction with care, i.e., a lack of communication from the GP is when the GP is
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reluctant to place a note in a patient’s record with a diagnosis of AD (Schoenmakers et
al., 2009). Specifically, some of the feelings patients have once they receive a diagnoses
of AD are the shame, disgrace, humiliation, and possible stigma of having a death
sentence. However, in contrast, the early diagnosis offers patients and their family’s time
to prepare for the more difficult stages of AD. The candor of discussing the disease and
providing early counseling far outweighs the negative connotations (Okie, 2011). In
addition, some doctors may lack specific training for evaluating and treating the elderly
(Schoenmakers et al., 2009).
Current projections for new cases of AD indicate by the year 2040, more than 80
million people will be affected by AD (Forlenza, Diniz, & Gattaz; 2010; Leifer, 2009). A
meta-analysis of the approximate prevalence of AD in the United States indicates an
increase from 1% at 65-69 years of age, to 13% to 17% at 85-89 years of age, and 24% to
31% at 90-94 years of age (Bassil & Grossberg, 2009). I suggest use of the phrase,
Classic Alzheimer’s Disease Symptoms (CADS), which may be more suitable to assign a
patient living with what is thought to be AD rather than an unfounded diagnostic term as
AD. At this time, AD has not been absolutely diagnosed and after a patient dies, an
autopsy can be performed to examine brain tissue. During the autopsy, the results of the
autopsy can then be used to conclusively describe the cause of death due to AD
(Christensen & Lin, 2007). As Okie (2011) reported, some physicians and agencies avoid
the use of AD as the diagnosis or eliminate AD as a diagnosis from health services for the
patient (Okie, 2011). Patients and/or family members caring for a loved one may initially
seek help from their primary care physicians (PCPs; Leifer, 2009). In turn, PCPs must be
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aware of AD symptoms and should screen elderly patients for AD. Family doctors (73%)
and internists (11%) were the first physicians consulted regarding the concern of AD.
After reporting symptoms to their family doctors, 62% of patients with AD remained
undiagnosed (Leifer, 2009). The medical community described and referenced AD in two
primary resources the International Classification of Diseases (ICD) and/or the
Diagnostic and Statistical Manual: Edition IV (DSM). The need to examine the
utilization patterns with regard to the new NIA AD protocol exists because no other study
to date has undertaken this task. In order to examine the utilization patters of physicians
one must look closer at three key areas (a) a historical review of AD milestones, (b)
examine changes in ICD-9, ICD-10, and the DSM-IV, and (c) explore what new research
has discovered in the last 27 years in regard to AD diagnostic criteria by looking at the
new NIA AD criteria.
This chapter included the literature review, an explanation of the literature search
strategy, theoretical foundation, conceptual framework, and a review of the study’s key
variables and/or concepts.
Literature Search Strategy
The literature review began with a database search including EBSCO, Gale,
Proquest, Pubmed, Medline, Sage Journals, and published dissertations hosted at the
Walden University Library. Databases searched included, but were not limited to,
Academic Search Complete, CINAHL Plus with Full Text, Health Sciences: A SAGE
Full Text Collection, Heath and Medical Complete, Nursing & Allied Health Source,
MEDLINE, Opposing ViewPoints Resource Center, and Proquest Central. Thoreau, the
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Walden Library Virtual Catalog was consistently searched for additional articles.
Secondary sources included books specific to AD, caregiving, and books complementing
journal articles by the same authors. Other secondary sources were leads to primary
sources, including the American Psychiatric Association, World Health Organization
International Classification of Diseases ICD-10, Centers for Medicare & Medicaid
Services, and the Diagnostic and Statistical Manual of Mental Disorders. Tertiary
Alzheimer’s organizations available on-line such as Alzheimer’s Association,
Alzheimer’s Foundation, Alzheimer’s Foundation of America, National Institutes of
Health, and the National Institute on Aging lead to primary sources.
The following keywords were used: Alzheimer’s disease, AD, Alzheimer’s
disease intervention programs, intervention programs for Alzheimer’s, magnetic
resonance imaging (MRI)s for AD, training, causes of death, leading causes of death in
the United States, old age, diseases, diseases of old age, aging process, caregiving,
caregivers, nursing, nursing homes, symptoms of AD, causes of AD, cure for AD,
treatment for AD, AD research, current AD research, AD studies, studies of AD, MRI
studies of AD, AD organizations, support groups for AD, local AD support groups for
AD, AD patients, and Alzheimer’s organizations.
This search covered years 2007 through 2015 but concentrated on the most recent
5 years. For this research, well over 400 sources were reviewed and only 65 were chosen
as the foundation for this research. No research was discovered that addressed my topic,
but several theoretical models were found that parallel the theoretical foundation used for
this study.

30
Theoretical Foundation
Rogers’s (1985) Diffusion of Innovation (DOI) theory was appropriate for this
research because the DOI theory frames this research in such a way to collect quantitative
data and describe the data as to how, why, or why not, and at what rate new ideas or
concepts are used. This is the first application of the DOI theory to specifically study
physician knowledge, attitudes and utilization patterns of the NIA criteria for all-cause
dementia and the application of DOI theory is well documented in other healthcare
studies. The survey results, once applied to the DOI theory, can be used to spread new
ideas through social systems (Dingfelder & Mandell, 2011).
In figure 1 for example, as the DOI theory is applied to the new NIA AD
diagnostic criteria the first two stages are self explanatory, i.e., innovation—a new idea
(use of new NIA AD diagnostic criteria) and the second stage, innovative-decision
process—where a practice group is committed to pilot testing the new concept. In the
third stage of the DOI theory, dissemination is described and applied to inform users of a
new idea and encourage them to use the new idea, i.e., using the new NIA AD criteria. In
the fourth stage of the DOI theory, adoption, new users of the NIA AD criteria commit to
using the innovation, i.e., continue using the criteria to evaluate patients for early
diagnosis of AD. In the fifth stage, implementation, make the use of the NIA AD criteria
the gold standard, the standard test covered by insurance companies and used by doctors
for the assessment of patients with signs of AD. In the final stage, stage six is
maintenance—is described as sustainability and implies the innovative idea was
successfully adopted into the practice group requiring updates to policies or procedures
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(Dingfelder & Mandell, 2011).
In this case, the DOI theory is ideal because of the four primary research
questions proposed based upon a through literature review. The DOI theory and research
questions solicit respondents to add their specific dialog responses. This is important
because the DOI theory speaks to assisting in description of responses as to why or why
not and responses not listed in the survey. The DOI theory has been used to better
understand the dissemination and implementation of interventions in diverse fields, such
as HIV/AIDS, substance abuse, and conduct disorder (Dingfelder & Mandell, 2010).
Glasgow et al. (2012) also used the DOI theory to address the gap between current
knowledge and practice related to the area of dissemination. Glasgow et al. focused on
implementing research on five specific values: rigor and relevance, efficiency,
collaboration, improved capacity, and cumulative knowledge. Similarly, there is potential
for an intervention plan (that may be discovered through this research and presented in
Chapter 5) to advance physicians’ knowledge, attitudes, and behaviors for the early
detection of AD. Because there are similarities in the use of DOI to explore new ideas,
innovations, and specifically the implementation of new AD criteria, the DOI research
theory was selected for this study.
The DOI theory has a long and proven history specifically in terms of studying
conceptual ideas and evaluating empirical evidence (Dearing, 2009). Examples of how
the DOI theory has been resourceful in research applicable to this study are well
documented. Aday and Cornelius (2006) reported the value and importance of using DOI
as a research theory also for similar research on HIV/AIDS and health interventions
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including smoking cessation and tobacco control. The DOI research theory can also be
applied herein.
Glasgow et al. (2012) used DOI theory in their research approach for the National
Institutes of Health approaches to dissemination and implementation science: current and
future directions, which explore approaches to start and prolong effective interventions.
Glasgow et al. reported that by closing the gap between optimal patients care and what
patients receive, there could be an impact on patients’ health. There is an indication that
one or more factors may lead toward an intervention that may detect and/or identify the
early signs of AD with the new AD criteria. The research herein may identify variables as
to why one or more groups may decline the use of the new AD criteria. Therefore, the
DOI theory is appropriate to this study, will aid in further describing the application in
later chapters, and may help explain data and possible correlation to social change
applications.
The survey instrument explores the three dependent variables through six
subquestions and applies the Knowledge, Attitudes, and Behaviors theoretical approach
using a modified version of the original model (KAB) theory and is simply Knowledge,
Attitudes, and Beliefs in this quantitative survey model (Aday & Cornelius, 2006).
Conceptual Framework
No one has determined or currently studied the knowledge, attitudes, and
behaviors (KAB) of physicians with respect to the new AD protocol and extent of its use
in clinical settings because current literature also indicates there are components strongly
suggesting a gap in KAB in treating/diagnosing AD patients, possibly due in part to
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current literature. There are conflicts in the literature with the current use of the term AD
to describe patients with AD. AD cannot be once and for all diagnosed until an autopsy is
performed and brain tissue is examined under a microscope to accurately make such a
diagnosis (Christensen & Lin, 2007). What continues to remain confusing is that if the
disease cannot be definitively detected unless examined postmortem under a microscope,
then how can a patient while alive can be labeled with AD. No detectable alignment or
collaboration is evident between the current version/edition of the ICD and the current
version/edition of the DSM, which physicians may reference to diagnose patients with
AD. I will evaluate physicians’ KAB in regards to the use of the ICD, DSM, and the new
AD criteria as resources to detect/diagnose AD in light of the NIA and Alzheimer’s
Association new updated AD criteria after 27 years of research and release of their joint
study.
In order to not over simplify the complexity or stress the enormity of the problem,
the macro approach for describing the crux of the problem begins with the description of
the working definition of the term dementia and drills down to the very root of the
research. The term dementia describes a wide array of brain illnesses, AD being the most
common form of the disease. GPs use a variety of diagnostic tools such as family reports
about the patient and documenting changes in the patient. A Mini-Cog Assessment
(Mini-Cog) or a Mini-Mental State Examination (MMSE) may be administered by GPs to
evaluate a person for AD (Kamenski et al., 2009; Leifer, 2009). Leifer recommended
using the MMSE to screen for cognitive impairment. Leifer also recommended the
benefit of using the original Mini-Cog Assessment with the MMSE and then compare the
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two screening instruments to evaluate a person’s cognitive abilities when screening for
cognitive impairment. The Mini-Cog is widely accepted by GPs for the evaluation of a
person suspected of AD. The Mini-Cog itself is easy to use, brief, and not influenced by
education or language. The Mini-Cog uses the components of the MMSE that include
specifically the three-item recall, testing the person for the ability to recall three words
after roughly one minute, and a Clock Draw Test (CDT) provided in Figure 3 (Kamenski
et al., 2009). In the CDT, the patient draws a picture of a clock with as much detail (hour
hand, numbers 1-12 properly placed, and the current time) to assess the patient’s
understanding of time. Researchers have not conclusively indicated the relevance of the
MMSE and the Mini-Cog among many other similar cognitive exams used for early
detection and early intervention whereby the social change of staving off the early signs
or symptoms of AD would result (Kamenski et al., 2009). There is no scientific test for
those living with AD as of yet that accurately detects and ends with a conclusive
diagnosis of AD. Cognitive tests like these are inexpensive and offer doctors evidence to
test the patient for other diseases. The results of the family history, MMSE, and a CDT
may not be enough to accurately diagnose a patient with dementia like AD.

Test description
With the original form of the Mini-Cog a score of 0
to 3 marks is given for the recall test, one point being
given for each word remembered after the CDT. A
score of 0 or 2 is awarded for the CDT part of the test –
2 points for a correct drawing, none for a wrong one.

number 12 correctly positioned and the hour and
minute hands pointing exactly to 11 and 10; yellow
for a good clock face with minor errors but wrongly
positioned hands; and red for a clock face with major
errors, that is, with hands missing or numbers
wrongly ordered. Figure 1 shows examples
35 of three
different test results.

Figure 3. Modification of Clock Draw Test. Adapted from Kamenski et al., (2009).
Detection of dementia in primary care: Comparison of the original and a modified MiniCog Assessment with the Mini-Mental State Examination. Mental Health in Family
Medicine, 6(4), 209-217. Retrieved from
http//ezp.waldenulibrary.org/login?url=http://search.ebscohost.com/login.aspx?direct=tru
e&db=rzh&AN=2010620651&site=ehost-live

Figure 1 Examples of three different CDT results

Researchers published over the past 5 years identified errors of greater than 50%
in GP diagnosis from the results of family history, MMSE, and the CDT when diagnosing
a patient for AD because there may be other contributing factors influencing results of
MMSE, such as a recent stroke. Not all GPs use one or all of the tests to diagnose a
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patient for dementia-like AD. A gap exists in the standard use of results from family
history, MMSE, and the CDT to diagnose a patient with dementia-like AD (Mangilasche
et al., 2010).
The World Health Assembly is the governing body for the WHO. WHO manages
the standards for healthcare and standardizing the diagnostic classifications for all
epidemiological findings (International Classification of Diseases, 2011). WHO revised
and updated the International Classification of Diseases (ICD) and released the draft
version of ICD-10 in 2011. In Chapter 5, Part III, mental and behavioral disorders are
listed; yet, none of the F01-F09 codes includes diagnostic criteria for AD. F01 describes
vascular dementia; F02 describes dementia in other diseases classified elsewhere; F03
describes unspecified dementia; F04 describes amnestic disorder due to known
physiological condition; F05 describes delirium due to known physiological condition;
F06 describes other mental disorders due to known physiological condition; F07
describes personality and behavioral disorders due to known physiological condition; F08
is not listed and is omitted, and F09 describes unspecified mental disorder due to known
physiological condition (CMS, 2012, p. 227-231).
It is not until closer examination of code F02, dementia in other diseases
classified elsewhere, that Alzheimer’s G30, specifically G30.9, is listed among 21 subdiseases such as Creutzfeldt-Jakob disease, Parkinson’s disease, and vitamin B
deficiency. Under the heading of other degenerative diseases of the nervous system, types
of AD are listed as AD with early onset, late onset, other AD, and AD unspecified (CMS,
2012). Typical characteristics of Alzheimer’s disease, vascular dementia, dementia with
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Lewy bodies, mixed dementia, Parkinson’s disease, frontotemporal lobar degeneration,
Creutzfeldt-Jakob disease, and normal pressure hydrocephalus, which are also found in
the DSM-IV-TR (CMS, 2012). Arguably, coordinated consensus is lacking between the
ICD-10 and the DSM-IV-TR for defining the diagnostic criteria and symptoms of AD,
which GPs can in turn reference for an inferential diagnosis of AD. The DSM-IV-TR
described and listed criteria for a diagnosis of AD as seen in Figure 4. Both the ICD-10
and DSM-IV-TR lack consistency in cohesion and uniformity, which may lead to
misdiagnosis or failure in the early detection of AD. A recommendation by the medical
community at large and with the WHO to use the ICD-10 and/or the DSM-IV-TR
independently and/or dependently of one or the other.
In Figure 4 (which I created to illustrate) the diagnostic code of 294.1x,
according to American Psychiatric Association, 2000, defined as dementia of the
Alzheimer’s type. In figure 4, for example, if a patient presents with multiple cognitive
defects and the manifestation is accompanied by memory impairment A(1) and one or
more A(2) aphasia, apraxia, agnosia, or disturbance in executive functioning may result
in cognitive deficits. The course of decline is characterized of symptoms such as
presenting gradual onset and declining cognition. Additionally, criteria from category
A(1) and A(2) must not be due to other conditions such as: conditions of the central
nervous system, i.e., Parkinson’s disease, cerebrovascular disease, or neurosyphilis. The
flowchart and subset of criteria do align with the new NIA AD diagnostic criteria.
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Figure 4. Diagnostic Criteria for AD Per American Psychiatric Association.
Note: Modification of a table adapted from American Psychiatric Association. (2002).
Diagnostic and statistical manual of mental disorders IVth edition. Washington, DC:
American Psychiatric Association.
Next, I used a three-tier approach to establish the conceptual framework for the
micro discussion for this study. I began with a past to present approach describing three
key areas. The three key areas include a discussion of AD from a historical approach,
moving forward to a present understanding of AD, and discussion of an overview of
current diagnostic criteria that are associated with AD. The theoretical foundation is
discussed last.
A historical examination of AD illustrates various milestones in the historical
research of AD. Alzheimer first discovered AD through microscopic analysis and is
credited for identifying beta-amyloid plaques and neurofibrillary tangles (NFT) – signs
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physicians now see in autopsies and document in postmortem exams as a cause of AD
death (Snowdon, 2003). Moving forward, Snowdon conducted a longitudinal study that
provided empirical data and learned that, while some of the nuns he studied had either
more signs and symptoms or fewer signs and symptoms of AD, they had different
proportions of the disease seen during autopsy. Descriptive statistics have been used to
describe variables within various studies examining AD by such researchers as Vincent
and Velkoff (2010) who reported that by 2030, the population older adults would be
approximately 439 and a ratio of 1:5 will be age 65 and older. Independent variables such
as indirect cost of caring for persons with AD amounted to approximately $144 billion
dollars (Attea & Johns, 2010). Tiedeman et al. (2011) reported evidence that is seen in
MRIs and could be used in later stages of AD because of the same evidence seen in the
MRIs is also present at autopsy, all of which leads current research. Frantz (2011) listed
the new NIA and introduced the new criteria that were previously reported. The new AD
criteria are a revision after 27 years of scientific research and describe the stages of the
diagnostic criteria for AD.
Snowdon (2003) published results from his longitudinal research that focused on
postmortem results of dementia. Snowdon included 678 Catholic nuns ranging in age
from the mid 70s to 107 years old. Information obtained from the research included
midlife factors, physical and mental examinations, and neuropathologic data obtained
postmortem. Snowdon further expanded Alzheimer’s postmortem findings by confirming
that an increased level of plaque and tangles are associated with AD.
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In regards to the disease’s origin, Alzheimer encountered a 51-year-old female
known as Auguste D. in 1906. D displayed forgetfulness, confusion, and the inability to
speak clearly. Upon her death, Alzheimer conducted an autopsy and discovered, through
microscopic analysis, beta-amyloid plaques and NFT, signs now used in postmortem
exams to diagnose AD (Snowdon, 2003).
The Snowdon Nun Research use postmortem results and health histories. A
limitation to his research, he selected only 10 nuns for convenience with tracking rather
than all of the nuns over the course of his 10-year research. While nuns displayed few-tono symptoms of dementia before death, they had higher levels of plaques and tangles in
postmortem exams. The nuns who displayed more empirical AD symptoms, such as
memory loss, lack of concentration, and inability to speak, displayed a healthier brain
upon cranial autopsy (Snowdon, 2003). An increased understanding about the relation
between dementia and AD has grown as documentation of new patients and the
awareness of AD grew (Christensen & Lin, 2007). The following examples and
illustrations emphasize the importance and significance related to the selection for the
research methods used herein.
While dementia is the more common disease, AD is one of many categories of
dementia. AD is a term more appropriately used postmortem (Christensen & Lin, 2007).
Medical journals, research articles, and various publications use the term AD in the
context of a living person to describe symptoms that can only be cited as a cause of death,
and found in research literature again to describe a patient with the disease as a cause of
death. AD ranks sixth as a leading cause of all deaths in the United States and is the fifth
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In comparison to past understanding, Alzheimer’s Association recently formed a
joint task force with the National Institute on Aging to review and revise criteria and
guidelines for the diagnosis of AD. There are new diagnostic criteria for AD, which could
improve diagnosis and facilitate continued research for a cure for the disease. The
National Institute on Aging and Alzheimer’s Association recently partnered to publish
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new guidelines for the diagnosis of AD and reportedly the first update in over 27 years
from the original published guidelines (Frantz, 2011).
Frantz (2011) reported the new criteria describing three stages of the diagnostic
criteria, the first being Stage 1: Preclinical. Stage 1 Preclinical symptoms, such as
memory loss, may be absent or difficult to detect. Pathological changes may already be
seen using biomarker tests which measure beta-amyloid accumulation in the brain,
indicating that AD has begun. Other examples of biomarker tests may include measuring
tau protein levels in spinal fluid or using imaging equipment to evaluate brain shrinkage.
Stage 2: Mild cognitive impairment may be a transitional phase between normal
forgetfulness and memory loss associated with AD. About 50% of those with mild
cognitive impairment develop dementia of the AD type. Of those 50%, approximately
25% may recover or regain normal functioning over time. There is no standard
neuropsychological test to evaluate mild cognitive impairment. Consequently, because
there is no standardized test for mild cognitive impairment, physicians adapt existing
tests developed for other purposes. A pattern of change in cognition, impairment of one
or more abilities, inability to function independently, and absence of dementia may be
indications of mild cognitive impairment. Stage 3: Dementia, is characterized by
symptoms where memory, thinking, and cognitive abilities are so severely impaired that a
person cannot function independently are indications the person has dementia. A
diagnosis of AD depends on clinical signs and symptoms with tests to rule out other types
of dementia or other diseases.

43
A diagnosis of AD with the new criteria recognizes the disease develops over
time, starting slowly and becomes more aggressive. The criteria for a diagnosis of AD
must include at least two cognitive domains such as memory loss, loss of executive
function, loss of visuospatial ability, and loss of fluency with language, and behavior and
personality change. A good example of memory loss in AD patients is seen when the
patient attempts to learn new information and recall what to do with the new information,
that is, stating to the patient that it is time to eat and the patient is unable to prepare to
dine. Other examples of memory loss may include the person displaying difficulty using
higher cognitive skills to assess situations for safety, evaluating risks of crossing the
street, operating a vehicle, or even simple activities of daily living such as taking a bath
and getting dressed.
An example of visuospatial loss may be wherein the person has trouble
recognizing surroundings or family. An example of loss of language may be seen wherein
the person has difficulty coming up with the right words to articulate themselves. An
example of behavior and personality changes may be seen wherein the person might
demonstrate changes in personality such as agitation, apathy, mood changes, or
unacceptable social behavior.
The Alzheimer’s Association suggested that using biomarkers for testing patients
for AD. Although the biomarkers are currently in the test phase and are not meant for use
in the clinical setting, the guidelines recommend using the biomarkers with clinical
assessments to determine if a patient might be in the early stages of AD (Frantz, 2011).
The overarching hope with the new diagnostic criteria for AD is to help better identify
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people at a much earlier stage of AD, to find a way to delay the onset of AD symptoms
for 5 million Americans with the disease now and projections of an additional 16 million
in another 40 years, and to recommend protective actions that can now be taken in an
attempt to reduce risks associated with AD (Frantz, 2011).
Fearing et al. (2007) reported evidence that no known cause or treatment exists
for AD. The emerging literature from research in the past 5 years reinforced that there is
no known cause or cure for AD (Christensen & Lin, 2007). Fearing et al. stated there is a
need for GPs to receive more geriatric training and reported that additional research is
indicated to include the use of MRIs as part of AD screening and new terminology for
describing AD symptoms.
The past diagnostic criteria for AD is described in both the ICD and DSM,
literature and information regarding AD is updated and released by the NIA, and various
Alzheimer’s organizations (American Psychiatric Association, 2000, Christensen & Lin,
2007; CMS, 2012, Jack et al., 2011, McKhann et al., 2011; National Institutes of Health.
2009). What is not known per se is physicians’ KAB on the newest criteria for AD after
the NIA and Alzheimer’s joint effort releasing the updated criteria after 27 years of
research and to what extent the criteria are being utilized by MDs. The research questions
described in Chapter 1 are purposefully focused on physicians’ current level of
knowledge, attitudes, and behaviors and evaluated through Rogers’s DOI theory. The
rationale for the foundation of this theoretical research will extrapolate how physicians
adapt new AD criteria by adopting or not adopting the new criteria into their practice
using Rogers’s diffusion of innovation theory.
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The past understanding of the term AD is a standardized diagnostic category
according to the 2012 ICD-9-CM Diagnosis Code 331.0: Alzheimer’s disease, which was
converted in 2012 as ICD-10-CM G30.9, in which AD unspecified is used to label a
patient with the disease and to describe a disease from which a patient died and
found/listed on death certificates (Lakkireddy et al., 2007). Throughout the literature, the
incongruent use of AD was discovered, ranging from the use of a person alive or the
cause of death in other uses of the term AD. The current use of the term AD by the
medical community states AD cannot be definitively diagnosed until an autopsy is
performed by examining brain tissue under a microscope in order to accurately make a
diagnosis of AD (Christensen & Lin, 2007). Currently, brain samples are obtained
postmortem (Christensen & Lin, 2007).
In January 2010, President Obama endorsed the National Alzheimer’s Project
Act. The Act is focused on improving AD research and services at all levels, as well as
accelerating treatments to abate AD disease. The purpose of this research is to identify
gaps between GPs presently testing patients for early stages of AD and the new NIA AD
criteria. While there are many professional entities that have the responsibility for
establishing consensus on standards of practice such as WHO, I identified a gap in
standards to detect early stages of AD. In Figure 6, guidelines published by the
Alzheimer’s Association offer a checklist for early detection of AD entitled “Know the
10 Signs,” offering possible detection and early signs of AD that can be observed by the
person with the disease and/or a caregiver and reported to the physician, whereas in Table
3 the DSM-IV-TR provides the diagnostic criteria for dementia of the Alzheimer’s type
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and is the standard of diagnosis for AD.
Table 3 The Alzheimer's Association's 10 Warning Signs of Alzheimer's Disease (Alzheimer's
Association, 2012)
Alzheimer's disease (AD)
1. Memory loss that disrupts daily life. One of the most
common signs of Alzheimer's, especially in the early stages,
is forgetting recently learned information. Others include
forgetting important dates or events; asking for the same
information over and over; relying on memory aides (e.g,
reminder notes or electronic devices) or family members
for things they used to handle on their own.
2. Challenges in planning or solving problems. Some
people may experience changes in their ability to develop
and follow a plan or work with numbers. They may have
trouble following a familiar recipe or keeping track of
monthly bills. They may have difficulty concentrating and
take much longer to do things than they did before.
3. Difficulty completing familiar tasks at home, at work
or at leisure. People with Alzheimer's often find it hard to
complete daily tasks. Sometimes, people may have trouble
driving to a familiar location, managing a budget at work or
remembering the rules of a favorite game.
4. Confusion with time or place. People with
Alzheimer's can lose track of dates, seasons and the passage
of time. They may have trouble understanding something if
it is not happening immediately. Sometimes they may
forget where they are or how they got there.
5. Trouble understanding visual images and spatial
relationships. For some people, having vision problems is
a sign of Alzheimer's. They may have difficulty reading,
judging distance and determining color or contrast. In
terms of perception, they may pass a mirror and think
someone else is in the room. They may not recognize their
own reflection.
6. New problems with words in speaking or writing.
People with Alzheimer's may have trouble following or
joining a conversation. They may stop in the middle of a
conversation and have no idea how to continue or they may
repeat themselves. They may struggle with vocabulary,
have problems finding the right word or call things by the
wrong name (e.g., calling a watch a "hand clock").
7. Misplacing things and losing the ability to retrace
steps. A person with Alzheimer's disease may put things in
unusual places. They may lose things and be unable to go
back over their steps find them again. Sometimes, they
may accuse others of stealing. This may occur more
frequently over time.
8. Decreased or poor judgment. People with Alzheimer's
may experience changes in judgment or decision making.
For example, they may use poor judgment when dealing
with money, giving large amounts to telemarketers. They
may pay less attention to grooming or keeping themselves
clean.
9. Withdraw from work or social activities. A person
with Alzheimer's may start to remove themselves from
hobbies, social activities, work projects or sports. They
may have trouble keeping up with a favorite sports team or
remembering how to complete a favorite hobby. They may
also avoid being social because of the changes they have
experienced.
10. Changes in mood and personality. The mood and
personalities of people with Alzheimer's can change. They
can become confused, suspicious, depressed, fearful, or
anxious. They may be easily upset at home, at work, with
friends, or in places where they are out of their comfort
zone.

Normal aging
What's typical? Sometimes forgetting names or
appointments, but remembering them later.

What's typical? Making occasional errors when
balancing a checkbook.

What's typical? Occasionally needing help to use the
settings on a microwave or to record a television show.

What's typical? Getting confused about the day of the
week but figuring it out later.

What's typical? Vision changes related to cataracts.

What's typical? Sometimes having trouble finding the
right word.

What's typical? Misplacing things from time to time,
such as a pair of glasses or the remote control.

What's typical? Making a bad decision once in a
while.

What's typical? Sometimes feeling weary of work,
family and social obligations.

What's typical? Developing very specific ways of
doing things and becoming irritable when a routine is
disrupted.

Figure 6. Alzheimer’s Association’s 10 Warning Signs of Alzheimer’s Disease. Note:
Modification of a table adapted from Alzheimer's Association, (2012e). 2012
Alzheimer’s Disease Facts and Figures. Retrieved from
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http://www.alz.org/downloads/Facts_Figures_2012.pdf.
Dementia of the AD type must be differentiated from the typical deterioration in
cognitive functioning associated with aging. The onset of dementia of the AD type is
identified by one of two subtypes, which accompany early onset or late onset. The
definition of onset as a subset of dementia with the AD type is used if the onset occurred
at age 65 or under, whereas the definition of late onset as a subset occurs after age 65
(American Psychiatric Association, 2000). Figure 7 was briefly discussed in Chapter 1
and continues here to identify the diagnostic criteria per the DSM-IV-TR.
Table 2. Diagnostic criteria for 294.1x Dementia of the Alzheimer's Type (American Psychiatric Association, 2000).
A. The development of multiple cognitive defects manifested by both
(1). memory impairment (impaired ability to learn new information or to recall previously learned information)
(2). one (or more) of the following cognitive disturbances:
(a). aphasia (language disturbance)
(b). apraxia (impaired ability to carry out motor activities despite intact motor function)
(c). agnosia (failure to recognize or identify objects despite intact sensory function)
(d). disturbance in executive functioning (i.e., planning, organizing, sequencing, abstracting)
B. The cognitive deficits in Criteria A1 and A2 each cause significant impairment in social or occupational functioning and represent a significant decline
from a previous level of functioning.
C. The course is characterized by gradual onset and continuing cognitive decline.
D. The cognitive deficits in Criteria A1 and A2 are not due to any of the following:
(1). other central nervous system conditions that cause progressive deficits in memory and cognition (e.g., cerebrovascular disease, Parkinson's disease,
Huntingtons's disease, subdural hematoma, normal-pressure hydrocephalus, brain tumor)
(2). systemic conditions that are known to cause dementia (e.g., hypothyroidism, vitamin B12 or folic acid deficiency, niacin deficiency, hypercalcemia,
neurosyphilis, HIV infection)
(3). substance-induced conditions
E. The deficits do not occur exclusively during the course of a delirium.
F. The disturbance is not better accounted for by another Axis I disorder (e.g., Major Depressive Disorder, Schizophrenia).
Diagnostic criteria for 294.10 Dementia of the Alzheimer's Type Without Behaviorial Disturbance: if the cognitive disturbance is not accompanied by any
clinically significant behavioral disturbance.
Diagnostic criteria for 294.11 With Behaviorial Disturbance: if the cognitive disturbance is accompanied by a clinically significant behavioral disturbance
(e.g., wandering, agitation).
Specify subtype: With Early Onset: if onset is at age 65 years or below. With Late Onset: if onset is after age 65 years
Coding note: Also, code 331.0 Alzheimer's disease on Axis III. Indicate other prominent clinical features related to the Alzheimer's disease on Axis I (e.g.,
293.83 Mood Disorder Due to Alzheimer's Disease, With Depressive Features, and 310.1 Personality Change Due to Alzheimer's Disease, Aggressive Type).

Figure 7. Diagnostic Criteria for AD per American Psychiatric Association. Note:
Modification of a table adapted from American Psychiatric Association, (2002).
Diagnostic and Statistical Manual of Mental Disorders IVth edition. Washington, DC:
American Psychiatric Association; American Psychiatric Association.
The NIA described diagnostic AD criteria which updates previous AD diagnostic
criteria published 27 years ago by the National Institute of Neurological Disorders and
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Stroke (NINDS) and the Alzheimer’s Disease and Related Disorders Association
(ADRDA) workgroup in 1984 (Jack et al., 2011). The new NIA criteria are similar to
diagnostic criteria found in the DSM-IV-TR (American Psychiatric Association, 2000).
The focus of this research will target the need for the early detection of AD. As a
secondary outcome of this research, data may indicate the need for a team approach
directly involving the patient, family members/caretakers, and physicians. Research is
ongoing and offers hope. Currently, there is a need for physicians to concentrate on early
diagnosis and treatment of AD (Christensen & Lin, 2007). Christensen and Lin stated that
modern care of AD includes the use of screening tools and DSM-IV diagnostic criteria,
well suited for the management of AD medications used to treat AD patients, and regard
for the caregivers well-being. Physicians can use appropriate screening tools, DSM-IV
diagnostic criteria, management of medications for the AD patient, and inclusion of the
needs of the patients’ caregivers (Christensen & Lin, 2007).
An early diagnosis of AD may help ease tensions within the family and assist in
explaining why one’s loved one has had a change in personality, mood, activities, and
behavior. A physician’s early detection and diagnosis of AD may assist in prompting and
facilitating the necessity for reviewing family finances, legal planning, discussing home
and long-term care alternatives and evaluation of safety practices of eliminating
automobile responsibilities (Leifer, 2009). The prompt actions of a physician to detect
and record a diagnosis of AD may positively affect social change. By leveraging routine
procedures for the early detection of AD in primary care offices, clinics, and beginning
early diagnostic evaluations for persons suspected with AD symptoms, it may promote
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the need to partner with those that are like minded, providing care planning at the earliest
time following a diagnosis of AD. Subsequently, this would promote the importance of
documenting the diagnosis and care plan in the person’s medical record. In some
instances, physicians are discouraged to document a diagnosis of AD (Attea & Johns,
2010).
Today, patients with AD or their loved ones oftentimes realize early on that
something is wrong; either the patient suspects memory loss or is observed by their loved
ones as having memory loss. At this point, problems with relationships are present almost
90% of the time and the patient knows something is wrong. Okie (2011) suggested the
early detection and diagnosis alleviates the stress of suspecting something else is going
on with one’s health. Even with therapy to slow down or abate the progression of AD, the
effective approach to deal with AD is detecting the disease as early as possible (Okie,
2011).
A gap in the existing standards for testing for AD dementia, the lack of early
detection tests to diagnose AD, and the combination of an MRI prescribed as a diagnostic
tool for assessing dementia is evident in current literature. More training for GPs is
needed in the diagnostic tools for treating dementia AD. Universal evidence-based
training is indicated for all disciplines at all levels for professionals and paraprofessionals
(Gould & Reed, 2009). Fearing et al. (2007) illustrated in the Cache County Research of
Aging close proximity of clinically diagnosed AD matching similarly diagnosed AD
subjects with postmortem confirmation of the disease using MRI technology. Fearing et
al. postulated the Cache County Research on Memory and Aging holds evidence that
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supports quantitative MRIs could be used in helping to diagnose AD in later stages of the
disease process.
As recent as 2008, researchers in France used an MRI to analyze whole-brain
anatomy, which evaluated patients with AD with similar ages as control subjects. The
MRI utilized a support vector machine as a means to better classify segments of wholebrain imaging (Magnin et al., 2009). The research included a study of gray matter from
16 patients with AD during autopsy. The researchers used resampling and statistical
formulas extrapolating data to project robustness of the research results (Magnin et al.,
2009). Consequently, the results demonstrated nearly 95% correct classification for AD,
the control subjects yielded a mean specificity of nearly 97%, and the mean sensitivity
was said to be nearly 92%. The researchers stated their use of MRI and testing
methodology could statistically detect AD and consequently assist in the early detection
of AD (Magnin et al., 2009).
The time and the need for a reliable test for the early detection of AD has arrived.
Recent projections forcast that by the year 2040, more than 80 million individuals will be
affected by AD (Forlenza et al., 2010). Current AD testing protocols do not include
ordering an MRI for the early detection of AD because doing so is not the standard of
care presently practiced in the United States due to the expense and lack of insurance
approval, as it may not be medically indicated. In order for the MRI to become approved
for the early detection of AD, the MRI could become the litmus test for the evaluation of
AD. The need to revise current GP protocols when diagnosing dementia-like AD patients
is based upon findings in current literature and case studies within the past 5 years. The
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need to address a new combination of diagnostic standards to accurately describe patient
symptoms is proposed, establishing a standard AD test, and possibly including an MRI in
the early phase to detect AD as a baseline for comparison in the secondary phase of AD
where MRIs have been most effective at detecting AD. The initial review of literature for
the past 5 years indicates GPs missed diagnoses of AD patients. The need for this
research may have lasting positive societal changes in the elderly wherein projections for
AD are estimated that every 1/3 of every minute someone new develops AD. AD cases
will significantly increase as early as 2040 or 2050 (Christensen & Lin, 2007).
However, until further research and the scientific/medical community prescribes
the use of MRIs as a primary tool to clinically diagnose AD patients, new research
presents GPs with an in office diagnostic test. Jack et al. (2011) reported the criteria for
the clinical diagnosis of AD established by the National Institute of Neurological and
Communicative Disorders and Stroke (NICDS) and the ADRDA going back as far as
1984. Jack et al. stated that if formal cognitive testing is not feasible, then cognitive
functions could still be assessed. For example, the clinician can ask the patient to learn an
address during the interview and ask the patient to recall the address a few minutes later
(e.g., 3913 Pheasant Lane, Modesto, California). On the other hand, the clinician may ask
the patient to name three items (e.g., a note pad, a stapler, and a pen), place them in
various locations around the room and later ask the patient to recall the location of the
items and recall the names of the items. The convenience of such a test does not require
any expensive equipment, may be less sensitive to subtle cognitive dysfunction during
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early stages of MCI, and do not typically evaluate cognitive domains beyond memory
(Jack et al., 2011).
Several researchers reported that there will be increased numbers of AD over the
near future. Christensen and Lin (2007) indicated the number of people in the United
States with AD could triple by 2050 and currently there are over 5 million with AD. The
challenge is to discover an early diagnosis of AD before the actual onset of dementia. A
confounding issue with discovering an early diagnosis lies within the early symptoms of
the disease itself. Magnin et al. (2009) stated that new technology exists today offering
quantifiable evidence that MRIs, for example, offer proof that early detection of AD
exists possibly through whole-brain vector imaging. Forlenza et al. (2010) acknowledged
that challenges adopting new and promising procedures are in the experimental phases,
some yet require validation, and the massive effort to introduce new information into
clinical practice requires refinement and operational acceptance within the health care
system.
AD is not observable per se; only symptoms and behaviors or signs patients
display suggest a patient might have dementia or later stages of AD. Early signs of AD
may go undetected for several years. Currently, research is underway to discover the
etiology, develop accurate diagnostic tests, find effective treatment, and find a cure for
AD (American Psychiatric Association, 2002; Christensen & Lin, 2007; Fearing et al.,
2007; Forlenza et al., 2010).
The National Institute on Aging and the Alzheimer’s Association published new
criteria for the diagnosis of dementia due to AD identifying three categories: (a) Probable

53
AD dementia, (b) Possible AD dementia, and (c) Probable or possible AD dementia with
evidence of AD pathophysiological process. The first two categories (Probable AD
dementia and Possible AD dementia) are intended for all clinical settings. The third was
established for research intentions only (McKhann et al., 2011).
The National Institute on Aging and the Alzheimer’s Association developed a
new standard of practice for the clinical diagnosis of AD. According to the workgroup in
cooperation with the National Institute on Aging and the Alzheimer’s Association, two
sets of criteria were developed: (a) core clinical criteria that could be used by healthcare
providers without access to imaging techniques or cerebrospinal fluid analysis, and (b)
research criteria that could be used in clinical research settings that include clinical trials
(Albert et al., 2011). This research will concentrate on the first core clinical criteria.
Albert et al. stated that because AD is a slow and progressive disease without a defined
onset of the disease, it is difficult for clinicians to identify transition points for individual
patients because each patient presents different signs and symptoms or may be
asymptomatic. What is now known about AD is that an AD patient’s doctor may not see
a predementia phase because it is difficult to identify (Albert et al., 2011).
For patients in the predementia phase, the workgroup recommended the term mild
cognitive impairment (MCI) due to AD to refer to the symptomatic predementia phase of
AD. This new criteria recommended by the National Institute on Aging and the
Alzheimer’s Association paralleled the same criteria proposed by the International
Working Group and assumed that it is possible to identify those individuals with AD
pathophysiological processes as the likely primary cause of their progressive cognitive
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dysfunction (Albert et al., 2011). Table 2 lists the standard of practice for clinical
diagnosis of Mild Cognitive Impairment. Figure 8 illustrates the new NIA AD protocols
which are the principle focus of this research. Figure 8 illustrates how the ICD-10 and
DSM-IV view AD by labeling AD as Mild Cognitive Impairment rather than AD, as
updated by the new NIA AD criteria.
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Table 2
Core Clinical Criteria for the Diagnosis of Mild Cognitive Impairment
Concern regarding a change in cognition

Impairment in one or more cognitive domains

Preservation of independence in functional abilities

Not demented

There should be evidence of concern about a change
in cognition, in comparison with the person's
previous level. This concern can be obtained from
the patient, from an informant who knows the
patient well, or from a skilled clinician observing
the patient.
There should be evidence of lower performance in
one or more cognitive domains that is greater than
would be expected for the patient’s age and
educational background. If repeated assessments are
available, then a decline in performance should be
evident over time. This change can occur in a
variety of cognitive domains, including memory,
executive function, attention, language, and
visospatial skills. An impairment in episodic
memory (i.e., the ability to learn and retain new
information) is seen most commonly in MCI
patients who subsequently progress to a diagnosis of
AD dementia.
Persons with MCI commonly have mild problems
performing complex functional tasks that they use to
perform previously, such as paying bills, preparing a
meal, or shopping. They may take more time, be
less efficient, and make more errors at performing
such activities that in the past. Nevertheless, they
generally maintain their independence of function in
daily life, with minimal aids or assistance. It is
recognized that the application of this criterion is
challenging, as it requires knowledge about an
individual's level of function at the current phase of
their life. However, it is noteworthy that this type of
information is also necessary for the determination
of whether a person is demented.
These cognitive changes should be sufficiently mild
that there is no evidence of a significant impairment
in social or occupational functioning. It should be
emphasized that the diagnosis of MCI requires
evidence of intraindividual change. If an individual
has only been evaluated once, change will need to
be inferred from the history and/or evidence that
cognitive performance is impaired beyond what
would have been expected fro that individual. Serial
evaluations are of course optimal, but may not be
feasible in a particular circumstance.
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The criteria for Probable AD dementia: Core clinical criteria are presented in
Figure 8.
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   Probable	
  AD	
  dementia	
  is	
  diagnosed	
  when	
  the	
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  in	
  Table	
  1	
  
and	
  has	
  the	
  following	
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A	
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  onset.	
  Symptoms	
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  a	
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  over	
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  to	
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  not	
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or	
  over	
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  or	
  days;	
  
B	
   Clear-‐cut	
  history	
  of	
  worsening	
  of	
  cognition	
  by	
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  or	
  observation;	
  and	
  
C	
   The	
  initial	
  and	
  most	
  prominent	
  cognitive	
  deficits	
  are	
  evident	
  on	
  history	
  and	
  
examination	
  in	
  one	
  of	
  the	
  following	
  categories.	
  
D	
   Amnestic	
  presentation:	
  	
  It	
  is	
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  syndromic	
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  of	
  AD	
  
dementia.	
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  information.	
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  of	
  cognitive	
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  in	
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  Table	
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E	
   Nonamnestic	
  presentations:	
  
	
  	
   1	
   Language	
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  The	
  most	
  prominent	
  deficits	
  are	
  in	
  word-‐finding,	
  but	
  
deficits	
  in	
  other	
  cognitive	
  domains	
  should	
  be	
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   2	
   Visuospatial	
  presentation:	
  	
  The	
  most	
  prominent	
  deficits	
  are	
  in	
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  object	
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  impaired	
  face	
  recognition	
  simultanagnosia,	
  and	
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  in	
  other	
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  domains	
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  be	
  present.	
  
	
  	
   3	
   Executive	
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  The	
  most	
  prominent	
  deficits	
  are	
  impaired	
  reasoning	
  
judgment,	
  and	
  problem	
  solving.	
  Deficits	
  in	
  other	
  cognitive	
  domains	
  should	
  be	
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F	
   The	
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  of	
  probable	
  AD	
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  should	
  not	
  be	
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  when	
  there	
  is	
  
evidence	
  of	
  (a)	
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  concomitant	
  cerebrovascular	
  disease,	
  defined	
  by	
  a	
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  of	
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  the	
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  or	
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  or	
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  hyperintensity	
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  or	
  (b)	
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  of	
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other	
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  or	
  (c)	
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  of	
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  or	
  (d)	
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  of	
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  or	
  non-‐fluentagramatic	
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  progressive	
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or	
  (e)	
  evidence	
  for	
  other	
  concurrent,	
  active	
  neurological	
  disease,	
  or	
  a	
  non-‐
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  medial	
  comorbidity	
  or	
  use	
  of	
  medication	
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  on	
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Figure 8. Probable AD dementia: Core Clinical Criteria. Note: Modification of a table
adapted from McKhann et al. (2011). The diagnosis of dementia due to Alzheimer’s
disease: Recommendations from the National Institute on Aging-Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer’s disease. Retrieved from
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http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312024/?tool=pubmed. Doi:
10.1016/jalz.2011.03.005
An evaluation by the GP and/or PCP of the person reporting to said individuals
can be clinically evaluated using the new criteria. The criteria for all-cause dementia:
core clinical criteria and other diseases ruled out for consideration for a diagnosis of
MCI. The use of these criteria is then necessary to follow in the continued evaluation and
diagnosis of AD. If evidence is present for a diagnosis of probable AD dementia from
Figure 8, then Figure 9 is invaluable to further refine a more specific diagnosis of
probable AD dementia (Albert et al., 2011; McKhann et al., 2011). I postulate that a gap
or incongruence exists wherein the ICD, DSM, and physicians’ knowledge of the new
NIA protocols for early AD diagnosis are incongruent and therefore emphasize the need
for the framework of this study including assessing their knowledge of the new NIA
protocols, attitudes for using the protocols, beliefs and behaviors to either currently use,
intend to use, or intend not to use the NIA new AD protocol.
With the application of the DOI theory and KAB theory design to these research
questions, this study will be used to explore and identify physicians’ current KAB
directly related to the new NIA AD criteria. The social change and potential implication
may advance the diagnostic phase of AD/CADS patients compared to singularly using
the ICD, DSM, or other previous methods spanning the course of the last 27 years.
Key Concepts
The following discussion will illustrate a connection and use for the KAB survey
and use of Rogers DOI theory to help better understand the relationship to the research
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questions and methodology used for this study. There are very few researchers who
explored the relationship(s) between physicians’ KAB (characteristics such as years since
graduating from medical school, area of specialty, percentage of patients aged 60 and
older, physician’s age, physician’s gender, knowledge of the new NIA protocol for early
detection of AD, and physician’s knowledge of AD) and the physician’s use, intended
use, or does not intend to use the new NIA AD protocol. Unlike other diseases, for
example, guidelines about early detection of breast cancer, colon cancer, and diabetes are
well documented. However, in a recent study, similar characteristics or for the purpose of
this study, six independent variables (IV), years since graduating from medical school,
area of specialty, percentage of patients aged 60 and older, physician’s age, physician’s
gender, and physician’s knowledge of AD from a knowledge score was provided by
completing a survey instrument (Wenger et al., 2009). In addition, Rogers’s DOI theory
has been used to better understand dissemination, application, and implementation of
interventions within the healthcare community such as developing interventions for
autism, HIV/AIDS, substance abuse, and conduct disorder (Dingfelder & Mandell, 2010).
Multiple researchers regarding AD underscored the importance and role families
play in the support of a person with AD. The following discussion is an outline of the
importance of families, support for the study, and reinforces the need for continued AD
research. Much of the scientific research presently underway is focused on discovering
the etiology of AD and a possible cure. The rationale for this study is supported by new
information regarding AD was released by the NIA changed how we look at the many
facets of AD and AD research.
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Families provide a bulk of the care for their loved ones with AD. The Alzheimer’s
Association, a voluntary health association with more than 70 chapters nationwide,
reported nearly 11 million American families and friends provided 12.5 billion hours of
unpaid care for persons with AD at an estimated $144 billion dollars (Attea & Johns,
2010). The significance of the older population, Figure 9, may indicate an increased level
of dependency on those younger than age 65 (Vincent & Velkoff, 2010). In addition,
Tiedeman, Kim, Flurie, Korch-Black, and Brandt (2011) stated that dementia is
characterized by deficits covering multiple areas of cognition. Such deficits are unable to
be explained by mere aging or a typical decline in function. Symptoms of a
neuropsychiatric are typically present as well as neurological findings. Etiology is a
further basis for dementia. The most common cause for dementia is AD. Other causes are
mixed AD and vascular dementia, Lewy body dementia (DLB), and frontotemporal
dementia.
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Figure 3.

Distribution of the Projected Older Population by Age for the United States:
2010 to 2050
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MRI technology. Fearing et al. postulated that quantitative MRI (qMRI) could be used in
helping to diagnose AD in later stages of the disease. For now, AD can be 100%
confirmed as a diagnosis for cause of death under microscopic examination during
autopsies, but not confirmed in the living (Christensen & Lin, 2007). While there are
various types of dementia and treatment for symptoms of AD, AD has no cure and is a
diagnosis of exclusions made using the DSM-IV. The International Statistical Institute
dates back to 1893, documenting causes of morbidity.
A review of current literature demonstrates a gap in the difference in the degree to
which there is consensus/certainty about the diagnosis of AD after autopsy (high
agreement/certainty) versus when the patient is alive and no brain tissue has been
examined pathologically (lower agreement/certainty). With the advancement in research
in recent years, a comparison of ICD-9 and ICD-10 demonstrates a minimal description
of dementia like AD symptoms in ICD-9. In ICD-9, the term organic brain syndrome was
associated with what we more commonly refer to as AD. Organic brain syndrome was
coded as F-09, but with the release of ICD-10, the term organic brain syndrome was
updated to AD. Since the release of ICD-9 and ICD-10, AD has been continually
described as a disease within those living with AD rather than a cause of death as current
literature describes in some peer reviewed medical journals. Whereas the CADS implies
a patient displays or demonstrates signs/symptoms we now commonly refer to as AD, the
revised ICD-10 describes AD as a term assigned to patients which is counter to
Christensen and Lin (2007) and the Centers for Medicare & Medicaid (2012), which
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stated that AD cannot be 100% confirmed as a diagnosis for cause of death until
microscopic examination.
Incongruence and gaps are seen in the ICD-10 because of advancements and
updates have been seen over the past 27 years as seen in the NIA updated report in 2011.
The ICD-10 fails to describe the diagnostic criteria for AD by only describing other
diseases associated within the classification of dementia. In other words, the ICD-10 does
not address AD specifically, but rather combines AD with dementia, whereas the new
NIA calls out in clear specificity the diagnostic criteria. AD was first listed in ICD-10 and
revised the definition of AD as an organic brain syndrome as previously found in ICD-9.
The lack of diagnostic criteria in the ICD creates a gap for healthcare providers. The new
release of the DSM in 2013 intended to describe and to categorize AD as a syndrome of
psychosis and depression previously used with AD. The ICD does list three stages of AD
and attributes related to each of the three stages. Yet, what are absent from the ICD are
diagnostic criteria for a differential diagnosis of AD. The DSM-IV does offer diagnostic
criteria as described earlier; however, what is described is not consistent with the new
criteria released by the NIA as of 2011.
The ICD-10 differs from the DSM-IV because the ICD-10 is a system used for
categorizing health issues and diseases globally, provides a systematic surveillance of the
health issues and diseases, and for making decisions about the budgeting of resources in
other countries. In contrast, the DSM-IV is a diagnostic manual used largely by medical
doctors such as psychologists and psychiatrists for diagnosing mental health disorders in
individual patients or groups in research studies which only reinforces the notion from
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the ICD-9 that AD is an outcome of growing old and previously described as organic
brain syndrome. AD has been consistently used to label a person with AD perhaps
because of the lack of a more definitive term (American Psychiatric Association, 2002;
Centers for Medicare & Medicaid 2012; Christensen & Lin, 2007).
Forlenza et al. (2010) acknowledged that there are indications for a standardized
diagnostic test or a checklist used to diagnose AD patients and training for the medical
profession. Alzheimer’s Association Quality Care Campaign has a number of
professional training initiatives: improving hands-on care for people with dementia in the
U.S.A., diagnosis and biomarkers of predementia in AD, and a reaction to Dementia
Diagnosis in Individuals with Alzheimer’s Disease and Mild Cognitive Impairment.
Figure 10 illustrates predictions of the widespread pattern AD may take in the coming
years. Christensen and Lin (2007) indicated the number of people in the United States
with AD could triple by 2050 and currently there are over 5 million with AD. In Figure
13, the higher proportion of AD can be seen in states such as Alaska, Washington, and
reaching as far south as Nevada. The significance of the rising numbers in AD and need
for early identification of AD onset is of the utmost concern because of the Autopsyconfirmed AD versus clinically diagnosed AD in the Cache County Research on Memory
and Aging substantiate, meaning that there will be an increase of AD (Christensen & Lin,
(2007). Science and medicine have not produced a reliable test to detect the early stage of
AD.
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the development of multiple cognitive incongruities to carry on day-to-day activities. The
DSM-IV does outrank or one might say takes precedence over the ICD-10 within the
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Prevalence
Alzheimer’s
Disease
Facts and Figures The DSM-IV is referenced offering
United
States of 2012
America
and
internationally.

diagnostic criteria for clinicians Activities of daily living (ADL) such as eating, dressing,
bathing, and toileting, and learning new activities or recall previous memories such as
names of spouses or family members of which are considered higher functioning
activities are examples of difficulties found in AD patients (Leifer, 2009). Figure 11
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illustrates a few of the ADLs provided by their caregivers. Furthermore, a failure at these
higher functioning psychomotor skilled activities and higher cognitive skills negatively
affects or impedes on social and/or occupational abilities. Characteristics of dementia of
the Alzheimer’s type displays signs of acute onset decline in daily activities, which are
also known as ADL, and are not due to other causes of mental decline of ongoing
Proportion of Caregivers of People with Alzheimer’s and Other Dementias
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Figure 11. Proportion of Caregivers of People with AD vs. People providing ADLs.
Modification of a graph adapted from Alzheimer’s Association, (2012c). 2012
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Alzheimer’s Association to publish new guidelines for the diagnosis of AD, reportedly
the first update in over 27 years from the original published guidelines (Frantz, 2011).
Frantz (2011) reported the new criteria describing three stages of the diagnostic
criteria, the first being Stage 1: Preclinical. Stage 1 Preclinical symptoms such as
memory loss may be absent or difficult to detect. Pathological changes may already be
seen using biomarker tests which measure beta-amyloid accumulation in the brain
indicating that AD has begun. Other examples of biomarker tests may include measuring
tau protein levels in spinal fluid or using imaging equipment to evaluate brain shrinkage.
Stage 2: Mild cognitive impairment may be a transitional phase between normal
forgetfulness and memory loss associated with AD. About 50% of those with mild
cognitive impairment develop dementia of the AD type. Of those 50%, approximately
25% may recover or regain normal functioning over time. There is no standard
neuropsychological test to evaluate mild cognitive impairment. Consequently, because
there is no standardized test for mild cognitive impairment (MCI), physicians adapt
existing tests developed for other purposes. A pattern of change in cognition, impairment
of one or more abilities, inability to function independently, and absence of dementia
may be indications of mild cognitive impairment with criteria seen in stage three. The
third stage is described as dementia due to AD with characteristics and symptoms where
memory, thinking, and cognitive abilities are so severely impaired that a person cannot
function independently indicating the person has dementia (Frantz, 2011). These three
stages of AD are what the NIA now use for a screening and diagnosis of AD, unlike the
ICD-10 or the DSM-IV. A diagnosis of AD with the new criteria recognizes that AD
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develops over time, starts slowly and becomes more aggressive. The criteria for a
diagnosis of AD must include at least two cognitive domains such as memory loss, loss
of executive function, visuospatial ability, and loss of fluency with language, and
behavior and personality. Examples of memory loss may include the person having
difficulty learning new information and/or executive functions wherein the person may
have difficulty evaluating safety risks or planning meals. An example of visuospatial loss
may be wherein the person has trouble recognizing surroundings or family. An example
of loss of language may be seen wherein the person has difficulty coming up with the
right words to articulate themselves or uses multiple words to describe a roll of paper
towels rather than just saying paper towel. An example of behavior and personality
changes may be seen wherein the person might demonstrate changes in personality such
as agitation, apathy, mood changes, or unacceptable social behavior.
The Alzheimer’s Association report suggested using biomarkers for testing patients
for AD. Although the biomarkers are currently in the test phase and are not meant for use
in the clinical setting, the guidelines recommend using the biomarkers with clinical
assessments to determine if a patient might be in the early stages of AD (Frantz, 2011).
The overarching hope with the new diagnostic criteria for AD is to help better identify
people at a much earlier stage of AD, to find a way to delay the onset of AD symptoms
for 5 million Americans with the disease now and projections of an additional 16 million
in another 40 years, and recommend protective actions we can take now in an attempt to
reduce risks now associated with AD (Frantz, 2011).
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Alzheimer discovered the very first case of AD over 100 years ago. Since the first
discovery of AD to the present time, run rate projections mirror numbers close to or at
epidemic proportions to the point, some may say AD has reached the scale of a
pandemic. Like many pandemics of the past, AD lacks an accurate etiology, lacks
consensus on diagnostic criteria, and lacks a treatment to cure the disease. Researchers
continue to study AD with anticipation of discovering an accurate test to detect AD.
Progress has been seen from various diagnostic exams such as mental exams, MRIs,
various biomarkers being studied to identify AD.
These efforts and many others are all in an attempt discover the cause of AD and
to develop a cure for AD. All known attempts to cure AD have failed to date, but some
prescription medications do allow the patient with AD a brief and better quality of life
before succumbing ultimately to AD. These examples and many other examples of
research are all in a massive effort to find the cause and cure for the deadly disease. The
true weakness for researchers lies only in the inability to identify the etiology and find a
cure for AD. The strength seen in AD research thus far is the vast amounts of research
dollars, committed researchers, and the backbone of family members keeping AD in the
forefront of our minds each day. Unlike other research, this study stands apart by
examining how physicians now choose or not choose to adapt the NIA’s new AD criteria.
Forlenza et al. (2010) reported there is a need to standardize AD testing or to use a
checklist and increase AD training for the medical profession.
The emerging literature from research in the past 7 years reinforces the theory that
there is no known cause or cure for AD (Christensen & Lin, 2007). Fearing et al. (2007)
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stated there is a need for GPs to receive more geriatric training and reported that
additional findings indicate the benefits of including MRIs as part of AD evaluations.
This is another example of emerging research from the scientific community supporting
the theory that as new emerging AD information surfaces.
I will focus on the question, how are physicians incorporating new research
evidence into clinical practice. As new results emerge, such as the new NIA AD criteria
for AD, in the pursuit of the etiology and cure for AD so should then the approach to
advance physician’s knowledge, attitudes, beliefs, and behaviors as they embrace the
newfound knowledge as using the DOI research theory. The research questions in
Chapter 1 are synchronous.
The following discussion illustrates a connection and uses of Rogers DOI theory
to help better understand the relationship to the research questions and methodology used
for this study. The following studies are classic examples of physicians adopting and
applying Rogers DOI theory to take data from numbers to application. For example,
physicians set out to evaluate the effectiveness of specific interventions on the adoption
of medical evidence as applied to clinical practices. The results from this study indicated
that the regularity of contact to strategies for furthering the acceptance of medical
evidence into clinical practice convincingly affects their perceived effectiveness
(Borenstein et al., 2003). In another example, in a recent study examining the opportunity
to optimize technology and update imaging equipment to current trends, the researchers
applied the DOI theory (Reiner, 2012). This is an interesting study given the fact that the
NIA admits there are opportunities for the detection of AD early in patients, yet little is
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known about cost versus benefit at this time to use imaging equipment for the early
detection of AD symptoms (McKhann et al., 2011). In another study investigating using
surgical innovations and associated factors, which prompt lymph node biopsy for breast
cancer, used Rodgers DOI theory to advance an intervention plan identifying sentinel
events (Wright, Gagliardi, Fraser, & Quan, 2011).
Therefore, the use of the DOI theory is applicable to this study by using the KAB
theoretical approach to design the primary research questions and associated subquestions
(Aday & Cornelius, 2006).
Summary and Conclusions
The overarching theme from the literature reviewed indicates little if any
knowledge is known about the physicians and the choice to use or not use the new NIA
AD diagnostic protocol. The literature review demonstrates the gap in current knowledge
regarding the utilization patterns of physicians’ use or choice to not use the new NIA AD
diagnostic criteria. As of this time, no other researchers have investigated the utilization
patterns of the NIA protocol by physicians. The benefits from this research will advance
the current knowledge of the relationship between the various independent variables
(potential predictors of use) and the dependent variable (use/non-use) by physicians’.
Chapter 3 is a detailed discussion of the research methodology and a rationale for
the approach.
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Chapter 3: Research Method
Introduction
The purpose of this study was to determine whether physicians’ knowledge and
background characteristics were associated with their use of, intention to use, or intention
not to use the NIA protocol for the early detection of AD. I found no research that
examined whether physicians are implementing or intend to implement the NIA’s new
recommendations, or how their implementation or intended implementation relates to
their knowledge and background. This chapter includes a discussion of the research
design, rationale, methodology, and threats to validity.
Research Design and Rationale
The methodology for this study was a quantitative correlational analysis of
selected independent variables and outcomes. I explored three research questions that
reflect three dependent variables (current use of the NIA protocol, intention to use the
NIA protocol, and intention not to use the NIA protocol) and six independent variables
(years since graduating from medical school, area of specialty, percentage of patients age
60 and older, physician age, physician gender, and knowledge of AD). Results from the
survey instrument are expressed as percentages; descriptive and inferential analysis of the
data is discussed.
Analysis of the data consists of two levels: (a) descriptive statistics describing the
study sample and data and (b) a series of bivariate tests to identify any statistically
significant associations of the independent variables with the dependent variables. DOI
theory was used as a theoretical framework to help understand the data. The independent,
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dependent and covariate variables directly related to this quantitative research study
design have been identified in Chapters 1 and 2.
The total of correct answers on the 30-item ADKS served as a measure of
participants’ knowledge of AD. The covariate variables aided in discussing the data in
two ways, that is, using their descriptive or inferential statistical values. The levels of
measurement for the variables included nominal, ordinal, interval, and ratio. The
appropriate statistic to use for the qualitative independent variables was Spearman’s rho
and for ordinal variables Pearson’s product-moment correlation coefficient. To avoid
family-wise errors (Type 1) due to the large number of variables being analyzed, I
conducted a Bonferoni adjustment to test significance and rule out random chances that
can be problematic with multiple comparisons. The adjustment checked the p value for
significance more stringently in order to reject the null hypothesis. For example, if one
were testing nine independent variables and each dependent variable, and the original
alpha level was .05 (p = .05), one would divide .05 by 9 and get p = .0056. The threshold
for significance was more stringent, adjusted to p = .0056, in order to reject the null
hypothesis. A multivariate analysis was not conducted to explore possible combinations
because none of the IVs was closely associated. A bivariate analysis was conducted to
evaluate IVs , which, if combined, would indicate they were stronger predictors than IVs
when linked in combination. Data collected from Part 1 of Appendix B was used in
Chapters 4 and 5 to describe statistics, providing a descriptive statistical analysis.
I used Rogers’s DOI theory as a theoretical framework in my analysis of data
collected through a survey designed similarly to a KAB survey; I illustrated my findings.
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I collected data through the survey for a 6-month period, which is described in detail. The
DOI theory assisted me in determining how data from this research may be used in the
development of an intervention plan that involves the adoption of the NIA protocol. The
rationale for selecting a KAB survey design for this research was based largely on
previous uses of KAB surveys in similar epidemiological research. However, the design
of this study primarily concentrated on advancing the understanding of physicians’
knowledge, attitudes, behaviors, and utilization patterns in relation to the NIA criteria for
all-cause dementia. A discussion of the exact survey methodology follows.
The ADKS, developed in 1988 by Dieckmann, Zarit, Zarit, and Gatz, was the first
published quiz to test the level of knowledge of Alzheimer’s disease among caregivers,
mental health professionals, nursing home staff, and other individuals interacting with
dementia patients. Results from the ADKS helped to develop an educational baseline to
stimulate dialogue, clarify fallacies, and appraise other educational programs (Gilleard &
Groom, 1994). Currently, the ADKS is one of only two published tests exploring
knowledge about dementia with a sample population consisting of members and
nonmembers of AD society. The ADKS is incorporated into this study to assist in
exploring physicians’ KAB. The ADKS consists of 30 questions and is found in Part 2 of
Appendix B.
As previously stated, Rogers’s DOI theory was applied to better understand the
dissemination and implementation of interventions within the healthcare community,
such as interventions for autism, HIV/AIDS, substance abuse, and conduct disorder
(Dingfelder & Mandell, 2010). Roger’s DOI theory was also used in a breast cancer risk
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assessment study, in which the researchers applied the DOI theory. In the breast cancer
risk assessment study, the researchers applied the results of the study and applied the DOI
theory to develop an intervention program (Guerra, Sherman, & Armstrong, 2009). The
application and use of DOI theory may also be helpful in further explaining the data in
Chapter 5.
The ADKS has been used in two other studies. The purpose of one of these
studies (Dieckmann et al., 1988) was to determine the AD awareness of undergraduate
students. The second study, conducted by O’Conor in 2001, was designed to determine
an effective way of educating people about AD (Sullivan, Finch, & O’Conor, 2003). The
ADKS is designed for use in research contexts and is capable of assessing knowledge
about AD among laypeople, patients, caregivers, and professionals (Carpenter, Balsis,
Otilingam, Hanson, & Gatz, 2008). The survey design for this research advances what
Dieckmann et al. and possibly others have done, in the sense that this study focuses on
physicians’ KAB related to the NIA Alzheimer’s diagnostic protocol. The ADKS could
be used to explore individuals’ current knowledge of AD. The results could be
administered again following a seminar, intervention, implementation of AD training, or
in-service to evaluate participant’s newfound understanding of AD and/or assess the
effectiveness of public health campaigns (Carpenter et al., 2008).
Other designs such as a qualitative approach were considered; however, these
designs failed to align with current research and studies discussed in Chapter 2 and would
not have facilitated direct comparison between samples. This research proposal does
include a recommendation for exploring the development or use of intervention program.

75
Methodology
The methodology was a quantitative correlational analysis of selected
independent variables and outcomes. My intention was to conduct a multivariate analysis
following the multivariate analysis of the data from Table 3 illustrated the data analysis
plan for this study. However, upon conducting the bivariate analysis and upon examining
the results of the bivariate analysis I discovered no associations and concluded the
multivariate analysis was unnecessary in the absence of significant results from the
bivariate analysis.
Table 3
Priori Power Analysis to Determine Total Study Sample Size
Exact correlation
Options
Analysis
Input

Output

Bivariate normal model
Exact distribution
A priori: Compute required sample size
Tail(s) = One
Correlation ρ H1 = 0.7071068
α err prob = 0.05
Power (1-β err prob) = 0.95
Correlation ρ H0 = 0
Lower critical r = 0.4259020
Upper critical r = 0.4259020
Total sample size = 16
Actual power = 0.9507112

Table 4 correlates the six research questions to the data analysis plan. A
multivariate analysis may illustrate a statistically significant relationship; with the
dependent variables, showing which independent variable may influence a physician to
use the new NIA protocol. For example, when examining knowledge (K) from the
acronym KAB, the results for K might have a 51% or greater statistical relationship with
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the dependent variables. A possible recommendation might be theoretically indicated and
associated with DOI theory to design an educational intervention.
Table 4
Data Analysis Matrix for DOI/KAB/Alzheimer’s Study
RQ A, B, and
C with
Associated
Sub-research
Question 1
Independent
Variable (IV)
exploredYears since
graduating
from medical
school

RQ A, B,
and C with
Associated
Sub-research
Question 2
Independent
Variable
(IV)
exploredPhysicians’
area of
specialty

RQ A, B,
and C with
Associated
Sub-research
Question 4
Independent
Variable
(IV)
exploredPhysicians’
age

RQ A, B, and
C with
Associated
Sub-research
Question 5
Independent
Variable (IV)
exploredPhysicians’
gender

RQ A, B, and
C with
Associated
Sub-research
Question 6
Independent
Variable (IV)
exploredPhysicians’
Knowledge of
AD

Physician’s
behavior of
testing and
diagnostic
criteria

Physician’s
behavior of
testing and
diagnostic
criteria

Physician’s
knowledge of
AD

Survey
Instrument
Part II
Bivariate

Physician’s
attitude
towards
using
reference
material
Survey
Instrument
Part II
Bivariate

RQ A, B,
and C with
Associated
Sub-research
Question 3
Independent
Variable
(IV)
exploredPercentages
of patients
aged 60 and
older
Physician’s
attitude
towards
using
reference
material
Survey
Instrument
Part II
Bivariate

KAB
Concept

Physician’s
knowledge of
Criteria

Data Source

Survey
Instrument
Part II
Bivariate

Survey
Instrument
Part II
Bivariate

Survey
Instrument Part
III
Bivariate

Median

Percentage

Percentage

Median

Male/Female
median

Number of
correct right or
wrong answers
from ADKS 30
question test

Source:
Schultz
Survey
Instrument

DV A, B, C,
and
Subquestions
1-6

DV A, B, C,
and
Subquestions
1-6

DV A, B, C,
and
Subquestions
1-6

DV A, B, C,
and
Subquestions
1-6

DV A, B, C,
and
Subquestions
1-6

DV A, B, C,
and
Subquestions
1-6 (ADKS 30
question test)

Literature
reference

(Wenger et al.,
2009).

(Wenger et
al., 2009).

(Wenger et
al., 2009).

(Wenger et
al., 2009).

(Wenger et
al., 2009).

(Wenger et al.,
2009).

Analysis
Procedures

Pearson’s or
Chi Square

Pearson’s or
Chi Square

Pearson’s or
Chi Square

Pearson’s or
Chi Square

Pearson’s or
Chi Square

Pearson’s or
Chi Square

Predictors for
using NIA
early
detection
protocol

Level of
Measurement
Response
value

A recommendation for an educational intervention was discovered through the
interpretation of the findings and discussed in Chapter 5. When I evaluated the data in
Chapter 4, a greater sensitivity response to the questions logically indicated a need for an
intervention. A discussion of the results of this research are presented in greater detail in
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Chapter 5, in which I suggested several possible directions or areas in which research
could continue.
Currently, I found no research on predictors for utilization of the NIA
Alzheimer’s assessment protocol by primary care physicians. While perspicacious,
existing published empirical data on physicians’ knowledge of and use of the NIA AD
protocol require further exploration.
Population and Sample
The targeted population (general practice physicians, family practice doctors, and
internal medicine physicians) for this research was selected by examining the number of
physicians within approximately 10 listed cities in California’s Central Valley region
using Superpages.com and information from a large medical treatment facility and Dr.
Joseph Provenzano, DO. Doctor Provenzano expressed an interest in helping me with
my research topic and became instrumental in connecting me with a large medical
treatment facility in Stanislaus County. The selection criteria were further refined to
Modesto and Stockton, California, which are located within Stanislaus County. Both
Modesto and Stockton are comparable in demographics (e.g., socioeconomic status, level
of education, income, race, sex, and access to care) to cities such as Sacramento, San
Jose, and San Ramon. The city of Modesto has 109 family medicine practices and general
practice surgeons listed with the local medical society. Physicians from two major
healthcare organizations will be invited to participate in the survey: Sutter Gould Medical
Foundation and Kaiser Permanente located in Stanislaus and San Joaquin counties in
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Northern California. With the use of both facilities, it should be possible to achieve the
minimum number of respondents.
In order to conduct the bivariate and multivariate analyses for the study, I needed
16 subjects for each predictor variable in the multivariate model (see Table 5), for a total
of 97 subjects for the study (see Table 6). I will discuss my actual power analysis in
Chapter 4 in detail.
Table 5
Priori Power Analysis to Determine Total Study Sample Size
Exact correlation
Options
Analysis
Input

Output

Bivariate normal model
Exact distribution
A priori: Compute required sample size
Tail(s) = One
Correlation ρ H1 = 0.7071068
α err prob = 0.05
Power (1-β err prob) = 0.95
Correlation ρ H0 = 0
Lower critical r = 0.4259020
Upper critical r = 0.4259020
Total sample size = 16
Actual power = 0.9507112

Table 6
Multivariate Regression Analysis to Determine Total Sample Size for Study
Anticipated effect size (f2)
Desired statistical power level
Number of predictors
Probability level
Results (minimum required sample size)

0.15
0.8
6
0.05
97

The individual predictor and total minimum sample size were calculated using the
G*Power 3.1 sample size calculator (Faul, Erdfelder, Buchner, & Lang, 2009). A one-
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tailed test was selected because a one-tailed test provides more power than a two-tailed
test and because multiple factors will be examined (Faul et al., 2009). A two-tailed test
was rejected, given that responses to my survey questions are mostly dichotomous and I
am not concerned about the direction of the association, as with clinical trials dealing
with medication and therapies where adverse reactions (negative associations) are of
interest and concern. I determined my minimum sample size to be 97. Although the
minimum sample size is 97, I strived for a higher response rate in order to achieve a
higher sensitivity and greater statistical value (Faul et al., 2009).
The effect size was set at (f 2) = 0.15 (considered a medium effect size), and a
statistical power level set at 0.8. Six predictors were identified in Table 6 and accounted
for in the calculation to determine the minimum sample size, a probability level of 0.95,
and standard deviation of 0.5.
Participant Recruitment and Screening
I initially collaborated with Sutter Gould Medical Center, and this partnership
included the support of the medical director. I have spoken with the local chief of
operations, and she indicated she could assist in gathering a large group of physicians to
complete the survey instrument.
An invitation letter was sent to 200 potential survey participants from two of the
109 listed practices within Stanislaus County. The invitation announced the survey and
sought out voluntary participants. An ideal candidate for the survey was identified as
being a physician who was involved in diagnosing persons with AD and practices within
Stanislaus County. Prospective participants were screened via the survey instrument in
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Appendix B, Part 1. The exclusion population consisted of those individuals removed via
the survey instrument in this survey. The final sample size is discussed in Chapter 4.
Online Survey Procedure
The rationale for deploying the survey via an online format was thought to be cost
effective and time efficient, avoided the potential for duplication of data from the same
respondents, aided in tracking completion rates, was valuable in sending out reminders to
complete the survey, and assisted in all attempts to achieve the appropriate sample size.
The first part of the online survey prescreened volunteers and prevented unqualified
respondents from continuing the survey. Unqualified candidates (those who did not select
A for Question 1, selected a response other than A for Question 2, and selected a
response other than B for Question 3) were directed to the exit page of the online survey.
Disqualified volunteers were provided additional information regarding the NIA AD
protocol as well as an explanation for why they were not allowed to proceed with the
survey. Demographic data was collected through the survey. No identifiable information
was collected. Qualified candidates were prompted to complete the informed consent
form and were able to print a copy of the consent form. All parties acknowledged the
consent form electronically.
Respondents completed the online survey I developed and hosted by Qualtrics.
Several opportunities were presented at the start of each section and/or at the end of each
section for respondents to indicate whether they wanted to either exit or continue the
survey. I utilized Qualtrics online statistical software to build my survey instrument, and
then securely hosted the survey through Qualtrics. I subsequently performed quantitative
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analysis through my selected criterion using SPSS software. I coordinated my efforts
with my contact at a large medical facility in Stanislaus County in California to launch
my survey instrument. She and others at the facility assisted me by sending 900
invitations via a fax to their healthcare members and invited them to participate in my
online survey.
Data Analysis
Table 5 illustrates the six subquestions, the research theory behind each question,
the data source intended to gather the data for this research, the level of measurement, the
literature resource associated with subquestion, and intended analysis procedures.
The operational phase of the survey took place via notifying volunteer pool
participants the survey was active online via an email with instructions to begin the
online survey. The independent variables were physicians/clinicians and their responses
to survey questions. The dependent variables were either the physicians’ use or intent to
use of the NIA protocol. The covariate variables and confounding variables were
uniquely defined as independent variables that may influence a study but have a
relationship with independent or dependent data (Creswell, 2003).
The covariate variables for this study included demographical data such age, sex,
type of practice, and number of years since graduating from medical school and are cross
referenced to the survey questions. The data included were variables collected during the
sampling/completion of the surveys. Responses from Part 2 of the survey were scored
and compared to right and wrong responses documented by Carpenter et al. (2008). An
example of a sample item from the survey appears as, “True or False It has been
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scientifically proven that mental exercise can prevent a person from getting Alzheimer’s
disease.” Data was analyzed using IBM SPSS Statistics 21. Data were screened and
descriptive statistics used to summarize computed demographic characteristics of the
participants and responses to Part 2 of the survey. A comparative analysis evaluated
distributions on both independent and dependent variables to evaluate appropriateness of
various statistical procedures. The intent was to categorize responses by gender and age
concerning the survey instrument. A completed discussion and analysis of all data is
further discussed in Chapter 4.
I considered one area of investigation: to explore providers’ knowledge, attitudes
and utilization patterns of the new NIA AD protocol investigating provider perceptions
and opinions regarding the feasibility of incorporating the new NIA AD criteria
recommended by the NIA and Alzheimer’s Association through responses to the two
primary research questions and discussed next.
Research Questions and Hypotheses
Research Question 1: Are a physician’s background characteristics and knowledge
associated with the physician’s use of the National Institute on Aging (NIA) criteria for
the detection of Alzheimer’s disease (AD)?
Subquestion 1A: Is the number of years since a physician graduated from medical
school associated with that physician’s use of the NIA criteria for the detection of
AD?
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H01A: The number of years since a physician graduated from medical
school is not associated with that physician’s use of the NIA criteria for
the detection of AD.
Ha1A: The number of years since a physician graduated from medical
school is associated with that physician’s use of the NIA criteria for the
detection of AD.
Subquestion 1B: Is a physician’s area of specialty associated with that physician’s
use of the NIA criteria for the detection of AD?
H01B: A physician’s area of specialty is not associated with that
physician’s use of the NIA criteria for the detection of AD.
Ha1B: A physician’s area of specialty is associated with that physician’s
use of the NIA criteria for the detection of AD.
Subquestion 1C: Is the percentage of patients over the age of 60 years in a
physician’s practice associated with that physician’s use of the NIA criteria for
the detection of AD?
H01C: The percentage of patients over the age of 60 years in a physician’s
practice is not associated with that physician’s use of the NIA criteria for
the detection of AD.
Ha1C: The percentage of patients over the age of 60 years in a physician’s
practice is associated with that physician’s use of the NIA criteria for the
detection of AD.
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Subquestion 1D: Is a physician’s gender associated with that physician’s use of
the NIA criteria for the detection of AD?
H01D: A physician’s gender is not associated with that physician’s use of
the NIA criteria for the detection of AD.
Ha1D: A physician’s gender is associated with that physician’s use of the
NIA criteria for the detection of AD.
Subquestion 1E: Is a physician’s age associated with that physician’s use of the
NIA criteria for the detection of AD?
H01E: A physician’s age is not associated with that physician’s use of the
NIA criteria for the detection of AD.
Ha1E: A physician’s age is associated with that physician’s use of the NIA
criteria for the detection of AD.
Subquestion 1F: Is a physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, associated with that
physician’s use of the NIA criteria for the detection of AD?
H01F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is not
associated with the physician’s use of the NIA criteria for the detection of
AD.
Ha1F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is associated
with the physician’s use of the NIA criteria for the detection of AD.
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Research Question 2: Are a physician’s background characteristics and knowledge
associated with the physician’s intention to use the National Institute on Aging (NIA)
criteria for the detection of Alzheimer’s disease (AD)?
Subquestion 2A: Is the number of years since a physician graduated from medical
school associated with that physician’s intention to use the NIA criteria for the
detection of AD?
H02A: The number of years since a physician graduated from medical
school is not associated with that physician’s intention to use the NIA
criteria for the detection of AD.
Ha2A: The number of years since a physician graduated from medical
school is associated with that physician’s intention to use the NIA criteria
for the detection of AD.
Subquestion 2B: Is a physician’s area of specialty associated with that physician’s
intention to use the NIA criteria for the detection of AD?
H02B: A physician’s area of specialty is not associated with that
physician’s intention to use the NIA criteria for the detection of AD.
Ha2B: A physician’s area of specialty is associated with that physician’s
intention to use the NIA criteria for the detection of AD.
Subquestion 2C: Is the percentage of patients over the age of 60 years in a
physician’s practice associated with that physician’s intention to use the NIA
criteria for the detection of AD?
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H02C: The percentage of patients over the age of 60 years in a physician’s
practice is not associated with that physician’s intention to use the NIA
criteria for the detection of AD.
Ha2C: The percentage of patients over the age of 60 years in a physician’s
practice is associated with that physician’s intention to use the NIA
criteria for the detection of AD.
Subquestion 2D: Is a physician’s gender associated with that physician’s intention
to use the NIA criteria for the detection of AD?
H02D: A physician’s gender is not associated with that physician’s
intention to use the NIA criteria for the detection of AD.
Ha2D: A physician’s gender is associated with that physician’s intention to
use the NIA criteria for the detection of AD.
Subquestion 2E: Is a physician’s age associated with that physician’s intention to
use the NIA criteria for the detection of AD?
H02E: A physician’s age is not associated with that physician’s intention
to use the NIA criteria for the detection of AD.
Ha2E: A physician’s age is associated with that physician’s intention to
use the NIA criteria for the detection of AD.
Subquestion 2F: Is a physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, associated with that
physician’s intention to use the NIA criteria for the detection of AD?
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H02F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is not
associated with the physician’s intention to use the NIA criteria for the
detection of AD.
Ha2F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is associated
with the physician’s intention to use the NIA criteria for the detection of
AD.
Pilot Study
I attempted to get four subject matter experts to serve as my expert panel and to
review then comment on the pilot study. The expert panel members were physicians
meeting the same qualifications described in Appendix B. The purpose of the expert
panel served as a checks-and-balances mechanism for the survey instrument before
conducting the pilot study.
I conducted a pilot study to ensure that physicians understood the questions, to
verify the clarity of the question(s), and to check the cohesion/sequencing of the
questions. The number of participants needed for the pilot study is estimated at between
three and five. The respondents were asked to provide their feedback as part of their
instructions. For example, the respondents were asked to answer each question as though
they were answering the survey.
Respondents were asked to provide feedback to each question and invited to
provide general comments about the survey itself at the conclusion of the pilot survey.
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Comments from the pilot study were then evaluated and considered for incorporation
when and where indicated. The pilot study will not validate the actual survey instrument.
Rather, the pilot study provided an opportunity to make refinements based upon
respondent feedback. The pilot study was deployed in a similar fashion as the actual
survey instrument in the following sequence.
To begin, invitations to participate in the pilot study were sent to approximately
three to five candidates. In the invitation, I asked potential participants to complete the
pilot study and to provide feedback. The specific feedback sought from the pilot study
respondents related to the clarity of the questions, respondents’ understanding of the
questions and available responses, and the sequencing of the survey questions.
A reasonable expectation was that some candidates may not have the time or
strong enough interest to complete all of the steps necessary to complete the pilot study.
If two to five respondents complete the pilot study, there may be enough feedback to
address issues such as sequencing, clarity, and overall understanding of the instrument.
The pilot study respondents were tentatively identified as three physicians willing to
assist pro bono.
Once three to five strong candidates were identified by the initial invitation, they
received the pilot survey with instructions to answer each question as though they were
answering the actual survey instrument. Respondents were asked to provide feedback to
each question and invited to provide general comments about the survey itself at the
conclusion of the pilot survey. Respondents to the pilot survey were then asked to return
their completed survey instrument.
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I evaluated feedback from the pilot survey responses and received no indications
to make any corrections to the survey. Consequently, there were no changes made or
recommended and I shared this information with the research department at Walden
University. I requested permission to contact the survey pool to begin my survey and
received approval from Walden University (add the approval number here—unless it’s
already been given elsewhere). The respondents from the pilot study were included in the
survey pool.
Instrumentation
A combination of questions from this research discussed in Appendix B and the
addition of 30 questions from the AKDS (Carpenter et al., 2008) in totality served as the
backbone of this survey instrument. Permission to use the AKDS was received as seen in
the correspondence in Appendix A. The AKDS is well documented for assessing
respondent’s knowledge of AD. The additional 30 questions assisted in assessing
respondent’s knowledge of AD and added statistical value as related to Research
Question 6.
Carpenter et al. (2008) revised and increased the ADKS sensitivity to accurately
reflect current understanding of AD. Permission was sought and received from Carpenter
to use the 30 question ADKS within the scope of the research herein (see Appendix A).
The appropriateness of the 30-question survey in combination with this exploration may
further advance current knowledge of AD and possibly advance the benefits of early AD
diagnosis.
Carpenter et al. (2008) stated that an analysis of the psychometric properties of
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the ADKS indicate the scale has enough statistical sensitivity for reliability and validity.
In the development of the ADKS, the research was conducted specifically to develop a
survey instrument. As such, the population selected was chosen to validate the 21question
survey instrument for Carpenter’s research and subsequent development of one
instrument with thirty questions. Unlike Carpenter’s ADKS survey, which used a random
half of the (n = 384) initial respondents and reduced the survey population to (n = 26) for
the pilot study (Carpenter et al., 2008), I intend to use all of the data received after the
data are cleaned. According to Carpenter et al. (2008), the ADKS was proctored twice to
40 respondents and ranged in age from 22 to 87 years (M = 48.9 years, SD = 21.2), and
their scores on the ADKS ranged from 19 to 30 (M = 24.2, SD = 2.4), indicating
variability in the respondent’s knowledge about AD (Carpenter et al., 2008). The testretest interval ranged from 2 to 50 hr (M = 20.4, SD = 15.9), and the test-retest reliability
coefficient was .81, p < .001, indicating appropriate test-retest reliability (Carpenter et al.,
2008).
Carpenter et al. (2008) stated that validity was confirmed for the ADKS by
calculating data from performance on the ADKS and ratings of self-reported knowledge
about AD from the respondent pool. Data from specific groups/subgroups were
significant, that is, for dementia caregivers, r = .46; for AD professionals, r = .39; for
older adults without cognitive impairment, r = .41; and for undergraduates, r = 20
(Carpenter et al., 2008). Consequently, respondents do have some
understanding/knowledge of AD (Carpenter et al., 2008). The ADKS was used in other
applications to assist in training and the development of educational intervention
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programs (Carpenter et al., 2008).
Data Analysis
Data was analyzed using IBM SPSS Statistics 21. Completed surveys were
evaluated and screened for completeness. Incomplete surveys were eliminated from the
overall survey results. I conducted a bivariate linear regression analysis on selected
independent variables and the outcome/dependent variables. I selected independent
variables based on the literature and which variables hypothesized may be related to the
outcome. The rationale for selecting specific independent and/or covariate variables as
discussed in Chapter 2 suggested a possible independent or dependent relationship within
the six research questions which may identify why physicians will or will not use the
NIA protocol for the early detection of AD (Wenger et al., 2009).
For example, one research question examines years in practice might be
associated with the use or likely use of the protocol, and then I ran that analysis and
evaluated the data as possible strong predictors. I did this for several independent
variables. Then I selected the top variables with the highest statistical association or value
and ran the analysis in a model together to see if together or a combination of them gives
a stronger value. Next, I ran a multivariate regression analysis on my top independent
variables and my outcomes. After running combinations of these variables, I evaluated
the data to determine if I get a strong association value. After running various
combinations, I tried to identify and suggest a combination, which showed the strongest
association to potential predictors. Unfortunately, there were no significant combinations
to further report results from the multivariate analysis and terminated the multivariate
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analysis. I will present my findings from the bivariate analysis in Chapter 4 and discuss
the implications of the findings in Chapter 5 in detail.
Threats to Validity
Consideration for both internal and external validity was evaluated. A plausible
internal threat to internal validity was examined regarding the selection of variables. The
expert panel and the pilot study evaluated the selection criteria to both expose and
recommend solutions for correction. A possible threat to statistical conclusion lied in part
with the uncertainty of reaching the totality of expected responses to the survey
instrument. The approach taken to achieve successful completion of statistical analysis
was achieved by conducting a Priori Power analysis. The Priori Power analysis
mathematically calculated a minimal statistical sensitivity rate needed to achieve
significant value for the study. The number needed is 97 respondents. At this time, I
know of no other researcher exploring a similar topic and know of any existing threats to
external validity.
There are several strengths to the current study. The ADKS originally published
by Dieckmann et al. in 1988 consisted of a 30-item multiple-choice tool to evaluate what
respondents know about AD. Since then, the ADKS has been used throughout research
endeavors about AD with specific consideration for both dependent variables (e.g.,
Sullivan & O’Conor, 2011) and independent variables (e.g., Carpenter et al., 2008;
Proctor, Martin, & Hewison, 2002). Since 1988 and to the present time, much has been
learned and published about AD (Carpenter et al., 2008). The ADKS does not account for
current knowledge of AD today because of the advancements in testing and knowledge
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about AD. However, the ADKS was developed to address what was then currently
known in about AD in 2008 and was considered up to date (Carpenter et al., 2008).
Carpenter et al. acknowledged some internal consistency reliability being low and
attributed it to the true/false response format and relatively high item difficulty indexes
resulting in lower variances. Whereas internal threats posed similar issues again because
the data from the ADKS study have not been validated (Carpenter et al., 2008).
Ethical consideration were undertaken to ensure Institutional Review Board (IRB)
application was submitted and approved, consensus from my committee and University
Research Review was achieved, and all documentation was either emailed or faxed to the
IRB. Ethical consideration for survey participants was taken. Appendix B provides an
outline of the online survey beginning with prequalifying questions. If the participant
does not meet the inclusion criteria for the study, they were sent to an exit screen with a
hyperlink to where they may learn more about the newly released NIA AD criteria. I
completed the NIH Office of Extramural Research Protecting Human Research training
in preparation of deploying my survey instrument (Certification of training Number:
1153705) as seen in Appendix C.
The participant must acknowledge they are aware of and have receipt of
information for the informed consent before entering the survey. Participants may exit the
survey at any time and were presented with an exit screen with a hyperlink to where they
may learn more about the newly released NIA AD criteria. Participants’ information
collected from the survey instrument and responses were encoded into an Excel
spreadsheet that was then password protected. All survey data was backed up, virus
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protected, password protected, and stored on password encrypted external hard drive. All
collected information and results from the survey instrument were encoded to protect
respondents and to provide anonymity. All data were accessible via a secured and
password protected account and accessed by the researcher and research committee. The
data will be archived after 5 years. In my job, there are no conflicts of interest. I have no
affiliations to any research company, group, and/or individual.
Summary
In this chapter I addressed the approach this research utilized to answer the
primary research question. I will explore physicians’ knowledge, attitudes, and behaviors
toward the NIA AD new protocols. In addition, in this chapter I discussed the research
design, rationale, methodology, and threats to validity. In the following chapter, Chapter
4 the research data is presented.
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Chapter 4: Results
Introduction
The purpose of this study was to explore the relationship between six independent
variables and two dependent variables. The independent variables were: the number of
years since graduating from medical school, physicians’ area of specialty, percentage of
patients aged 60 and older, physicians’ age, physicians’ gender, and physicians’
knowledge of AD. The two dependent variables were (a) current use of the NIA protocols
and (b) intention to use the NIA protocol. This is how they appear in RQ1 and RQ2:
Research Question 1: Are a physician’s background characteristics and
knowledge associated with the physician’s use of the National Institute on Aging
(NIA) criteria for the detection of Alzheimer’s disease (AD).
Research Question 2: Are a physician’s background characteristics and
knowledge associated with the physician’s intention to use the National Institute
on Aging (NIA) criteria for the detection of Alzheimer’s disease (AD).
I examined the associations between the variables using a quantitative,
correlational research design, as described in Chapter 3. This chapter also details the data
analysis, such as descriptive statistics, univariate and bivariate analyses, as well as
outcomes from each detailed analysis performed. I will discuss the expert panel review,
the pilot study, data collection, characteristics of the study population, details of analysis,
and results, followed by a detailed discussion of each of the two research questions.
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Expert Panel and Pilot Study
Before launching my pilot study and during the development of my survey, I
sought the expertise and opinions of two clinicians, Dr. Amy Bader and Dr. Joseph
Provenzano. My purpose in asking for their opinions was to gain insight into the pilot
study process and eventually to obtain consensus validity of the full survey instrument.
Neither Dr. Bader nor Dr. Provenzno participated further after providing their initial
comments in serving as my expert panel review committee. Neither of them suggested
changes and had similar comments that the invitation was easy to follow and the survey
was easy to complete. I reported my findings to my committee members and to the
Walden University Institutional Review Board. Subsequently, I was allowed to conduct
my pilot study (IRB approval number 03-10-14-011114).
Participants in the pilot study included four subject matter experts, physicians who
were similar to the participants for the main study. The physicians who participated in the
pilot study met the same qualifications and inclusion criteria for the study as described in
Appendix B. The pilot study provided an opportunity to make any changes or refinements
to the survey and/or the data collection process before launching the main study.
Two of the four participants did not respond. The other two participants
completed the online survey with no problems and indicated no changes were necessary
to the survey. Two participants had no suggestions for improvement and responded the
same, “no changes,” indicating they had reviewed the pilot study contents, had no
problems understanding the survey questions, and had no additional comments for
improvement. I shared these initial findings with my committee and the Walden
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University and requested permission to conduct the main study. I was granted full
permission to proceed with my data collection process. Walden University’s approval
number for this study is 03-10-14-0111148 expiring March 9, 2015. I did not include the
respondents from the pilot study in the survey pool, nor were they invited to participate in
the actual online survey instrument.
Data Collection
Qualtrics online statistical software was used to build my survey instrument, then
securely host the online survey, and subsequently perform quantitative analysis through
my selected criterion. A contact at a large medical facility in Stanislaus County,
California assisted me by sending 900 invitations via a fax blast to their members that
invited them to participate in my online survey. The survey instrument was deployed
online on March 19, 2014 and was closed on September 25, 2014 (six months and six
days). After screening potential candidates for eligibility to participate (described in
Chapter 3), study participants completed the informed consent process, answered the
survey questions, and submitted their responses electronically. I expected to meet my
minimum sample size within 90 days; however, because of low participation numbers (N
= 17) I consulted with my contact at the large medical facility, my committee, and the
Walden Institutional Review Board (IRB). I requested an extension of 90 additional days
to collect additional data. During this extension period, I was able to collect only 42
additional surveys. I consulted again with my contact at the large medical facility, my
committee, and Walden’s IRB committee and requested a second extension for data
collection. Additionally, I took the advice from my second committee member Dr. Stoodt
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and expanded my survey collection area over to the next closest county. I was more
purposeful in my approach and sent invitations with the online survey to specific
organizations with similar participant criteria within San Joaquin County. The new
survey base included agencies located within San Joaquin County, California and added
additional 30 respondents to my pool for a grand 89 respondents.
My efforts to achieve the minimum sample size began with a population of (N =
900) and expanded to (N = 2,700) potential participants, unfortunately, my efforts were
not successful in reaching the minimum sample size for this study. My contacts within
both counties sent each potential participant the initial invitation, which included the
online survey link and two additional reminders to complete the survey. In spite of my
efforts to recruit additional participants, I collected 89 surveys of which 17 were
disqualified because they were administrators and did not meet the inclusion criteria for
my study. Additionally, 18 other surveys were removed for due to incomplete answers
with too much missing data to compute any research variables. I consulted with my
committee members and the College of Health Sciences research coordinator, we decided
to suspend participant recruitment because of constraints of time and resources, and
established sufficient good faith effort was applied for participant recruitment. I received
approval to proceed directly to data analysis and interpretation given my concerted efforts
at trying to achieve the minimum sample size, and realizing that findings involved
required cautious interpretation given the reduced power of the study to detect an effect.
The Bonferroni adjustment is recognized to reduce the risk of type I error rates, also
known as false positives. Furthermore, the Bonferroni adjustment is an acceptable
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mathematical adjustment, commonly used by Epidemiologists, that provides valid and
reliable statistical data and effect power to identify type I errors (Bender & Lange, 2001).
While a Bonferroni adjustment is unnecessary with regard to sample size and p values
and the Holm calculation method, also used by Epidemiologists for other studies, it may
be more suitable for smaller sample statistical inferences (Aickin & Gensler, 1996). I
decided to use and apply the Bonferroni adjustment to my data set based upon the
consistent research findings on the topic of Bonferroni adjustments and the
appropriateness for application to my findings. The data collection remained true to the
plan as discussed in Chapter 3 and no discrepancies were further noted. In Chapter 5, I
will discuss in detail recommendations for future researchers interested in conducting
research with similar study subjects as this dissertation. I downloaded the final data to my
computer for analysis. I will discuss my results next.
Results
Characteristics of the Study Population
Again, I evaluated specific focused area: providers’ knowledge, attitudes and
utilization patterns of the new NIA AD protocol examining provider perceptions and
opinions regarding the feasibility of incorporating the new NIA AD criteria
recommended by the NIA and Alzheimer’s Association through responses to two primary
research questions. Because of the low return rate, both participants that were responsible
for diagnosing Alzheimer’s disease and those who were not were included in the study.
Findings from the overall sample were compared with those from the sample of eligible
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participants to confirm the findings. The overall sample consisted of 55 participants,
while the subset of qualified individuals consisted of 19 of the overall 55.
Overall sample. Within the overall sample, the vast majority of participants
predominantly practiced in Stanislaus County or San Joaquin County (54, or 98%). There
were 22 physicians and 33 nurses providing completed surveys. Twenty respondents
(36%) indicated they were responsible for making a diagnosis of AD. A majority of my
respondents (38, or 69%) was not board certified. Of those that responded (17, or 31%)
the 17 participants responding to the area of specialty not all could be grouped into
similar categories because respondent’s did not further identify their area, although
respondents were given the opportunity with option “c” as other to fill in their specialty
did not. For example, responses could have been nurse practitioner, non-NP, LPN, etc.
The majority of the overall sample was not responsible for diagnosing
Alzheimer’s patients within their role in the healthcare system (35, or 64%). The
respondents included physicians, nurses, and nurse practitioners and as such, I assumed
they had existing training or knowledge to be able to spot early signs of AD within the
limits of their clinical practice. Twenty-two respondents (40%) were aware and 32 (58%)
were not aware of the new NIA protocols. Slightly more participants were female (33, or
60%) than male (22, or 40%). Most participants were not board certified (38, or 69%).
The majority of participants did indicate they did not use the NIA criteria to diagnose
Alzheimer’s disease (46, or 85%). More than half the respondents indicated they did not
intend to use NIA criteria in the next 12 months (27, or 54%). Seventeen respondents
indicated they were board certified, however, not all of the respondents indicated their
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specialty as those that did and identified passing boards as a gerontologist or nurse
practitioner.
Of those respondents, one reported being a gerontologist; the others were board
certified or nurse practitioners. Regarding the knowledge assessment, scores ranged from
0 to 30 as reported from my from the ADKS survey portion of my survey. The sample’s
scores on this assessment ranged from 13 to 28, indicating none of the participants had
100% correct on this assessment; the maximum score was 28, or 93%. However, the
average score was 21.31, which corresponded with 71% correct. The standard deviation
of 2.79 indicated that much of the sample was clustered between the scores of 62%
correct to 80% correct. The average score of 71% indicates respondents knowledge of
AD may be lacking and thus provide an indicator for more AD training for healthcare
providers. Table 7 presents frequencies and percentages for selected nominal variables.
Table 7
Frequencies and Percentages for Selected Nominal Variables (N = 55)
Variables
Responsible for Alzheimer’s diagnosis
No
Yes
Predominant county of practice
Stanislaus or San Joaquin County
Tuolumne County
Gender
Female
Male
Board certified/“specialty”
No
Yes
Currently used NIA Criteria

n

%

35
20

64
36

54
1

98
2

33
22

60
40

38
17

69
31
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No
46
85
Yes
8
15
Note. Not all respondents answered questions relating to currently used and intend to use
NIA criteria. Due to rounding error, percentages may not add up to 100.
Participants in the overall sample ranged in age from 24 to 80, with an average
observed age of 51.02 years (SD = 13.72). Participants had graduated between 0 and 56
years before data collection, with an average length of 24.44 years since graduation (SD =
15.16). Participants reported the proportion of their patients who were older than 60
ranged between 0–100%; on average, 36.91% of participants’ patients were over the age
of 60 (SD = 27.53). Participants were also assessed for knowledge regarding Alzheimer’s
disease using the ADKS, and knowledge scores fell between 13.00 and 28.00. A perfect
score was not achieved representing 30/30 questions answered correctly. The scores
indicated a low knowledge of AD. The average score for the gathered sample was 21.31
(SD = 2.79). Table 8 presents means and standard deviations for continuous variables
evaluating data from 55 completed surveys.
Table 8
Means and Standard Deviations for Selected Continuous Variables (N = 55)
Variable

M

SD

Age
13.72
51.02
Years Since Graduating
15.16
24.44
Percent of Patients Older than 60
27.53
36.91
a
Knowledge
2.79
21.31
Note. Not all respondents answered questions relating to age, years since graduation,
percent of patients older than 60, and knowledge.
a
Knowledge was assessed using the correct results from the Alzheimer’s disease
knowledge test used in the survey with 30 True/False responses
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Subset data. Of the 20 who responded that they were legally responsible for
diagnosing Alzheimer’s disease, one responded that they were an RN, and was excluded
from the subset. Of those who provided their job specialty, one was a primary care
physician, one was an ophthalmologist, and one was an anesthesiologist. Demographic
information for the final subset of 19 (minus the RN) responsible for Alzheimer’s
diagnosis is presented in Table 8 below. A majority of this subset was from Stanislaus or
Joaquin County (18, or 95%) and were male (11, or 58%). More of this subset was not
board certified (13, or 68%) than were certified (6, or 32%). In addition, most did not use
the NIA criteria at the time of data collection (14, or 74%). Demographic information for
the subset of participants who were responsible for Alzheimer’s diagnosis are presented
in Table 9.
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Table 9
Frequencies and Percentages for Subset Sample (N = 19)
Variables

n

%

Predominant county of practice
Stanislaus or San Joaquin County
18
95
Tuolumne County
1
5
Gender
Female
8
42
Male
11
58
Board Certified
No
13
68
Yes
6
32
Currently use NIA Criteria
No
14
74
Yes
5
26
Note. Not all respondents answered questions relating to currently use and intend to use
NIA criteria. Due to rounding error, percentages may not add up to 100.
The subset of participants who were responsible for Alzheimer’s diagnosis ranged
in age from 28 to 79, with an average observed age of 50.68 years (SD = 13.26). These
participants had graduated between 1 and 50 years before data collection, with an average
length of 21.74 years since graduation (SD = 14.22). Participants reported the proportion
of their patients who were older than 60 ranged between 20–95%; on average, 42.25% of
these participants’ patients were over the age of 60 (SD = 18.95%). Participants were also
assessed for knowledge regarding Alzheimer’s disease using the ADKS, and knowledge
scores fell between 14.00 and 25.00. A perfect score was not achieved representing 30/30
questions answered correctly. The scores indicated a low knowledge of AD. The average
score for the gathered sample was 21.55 (SD = 2.39). Table 10 presents means and
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standard deviations for continuous variables evaluating the subset of participants who
were responsible for Alzheimer’s diagnosis.
Table 10
Means and Standard Deviations for Subset’s Continuous Variables (N = 19)
Variable

M

SD

Age
50.68
13.26
Years Since Graduating
21.74
14.22
Percent of Patients Older than 60
42.25
18.95
a
Knowledge
21.55
2.39
Note. Not all respondents answered questions relating to age, years since graduation,
percent of patients older than 60, and knowledge.
a
Knowledge was assessed using the correct results from the Alzheimer’s disease
knowledge test used in the survey with 30 True/False responses
I collected data using an anonymous online survey. The variables for the analysis
were obtained through the categorical responses of the participants from the online
survey instrument. I categorized the variables in nature from the multiple choice
responses collected from the survey instrument. Logistic regressions were conducted
separately on each subset of variables. For each research question, a bivariate analysis
was conducted using chi square analysis of the six covariates.
The following sensitivities for my data analysis were set in place as discussed in
Chapter 3. As outlined in Chapter 3, the individual predictor and total minimum sample
size were calculated using the G*Power 3.1 sample size calculator (Faul, Erdfelder,
Buchner, & Lang, 2009). I selected a one-tailed test, because a one-tailed test provided
more power than a two-tailed test and because I examined multiple factors (Faul et al.,
2009). I rejected using a two-tailed test because responses to my survey questions were
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mostly dichotomous. Based on these calculations, and assuming a medium effect
size (f 2 = .15) and assuming a generally accepted power of .80, approximately 97
participants are required to discern significant relationships at the α = .05 level.
After concluding the analysis, I conducted a post-hoc power analysis to determine
the power of each analysis to successfully reject the null hypothesis when it is in fact
false. Based on an alpha of .05, an achieved sample size of 55, and a normal distribution,
power for the analyses to inform research question one ranged from .06 to .23. Using the
same parameters, the power for the analyses to inform research question two ranged from
.05 to .67.
Results for the Bivariate Analyses
Research Question 1
Are a physician’s background characteristics and knowledge associated with the
physician’s use of the National Institute on Aging (NIA) criteria for the detection of
Alzheimer’s disease (AD)?
To examine the relationship between background characteristics and the use of
NIA criteria for the detection of Alzheimer’s disease, six simple logistic regressions were
first assessed through hypothesis testing. The resulting hypotheses were:
Subquestion 1A: Is the number of years since a physician graduated from medical
school associated with that physician’s use of the NIA criteria for the detection of
AD?
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H01A: The number of years since a physician graduated from medical
school is not associated with that physician’s use of the NIA criteria for
the detection of AD.
Ha1A: The number of years since a physician graduated from medical
school is associated with that physician’s use of the NIA criteria for the
detection of AD.
Subquestion 1B: Is a physician’s area of specialty associated with that physician’s
use of the NIA criteria for the detection of AD?
H01B: A physician’s area of specialty is not associated with that
physician’s use of the NIA criteria for the detection of AD.
Ha1B: A physician’s area of specialty is associated with that physician’s
use of the NIA criteria for the detection of AD.
Subquestion 1C: Is the percentage of patients older than 60 in a physician’s
practice associated with that physician’s use of the NIA criteria for the detection
of AD?
H01C: The percentage of patients older than 60 in a physician’s practice is
not associated with that physician’s use of the NIA criteria for the
detection of AD.
Ha1C: The percentage of patients older than 60 in a physician’s practice is
associated with that physician’s use of the NIA criteria for the detection of
AD.
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Subquestion 1D: Is a physician’s gender associated with that physician’s use of
the NIA criteria for the detection of AD?
H01D: A physician’s gender is not associated with that physician’s use of
the NIA criteria for the detection of AD.
Ha1D: A physician’s gender is associated with that physician’s use of the
NIA criteria for the detection of AD.
Subquestion 1E: Is a physician’s age associated with that physician’s use of the
NIA criteria for the detection of AD?
H01E: A physician’s age is not associated with that physician’s use of the
NIA criteria for the detection of AD.
Ha1E: A physician’s age is associated with that physician’s use of the NIA
criteria for the detection of AD.
Subquestion 1F: Is a physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, associated with that
physician’s use of the NIA criteria for the detection of AD?
H01F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is not
associated with that physician’s use of the NIA criteria for the detection of
AD.
Ha1F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is associated
with that physician’s use of the NIA criteria for the detection of AD.
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Because six analyses were conducted on the same dependent variable (use of the
NIA criteria for AD detection), a Bonferroni correction was applied to the resulting p
values. The critical alpha was divided by the number of times the analyses were
conducted on the dependent variable, and resulted in a final critical alpha of (.05/6), or
.008. Thus, significance was determined for any model or individual predictor if the
corresponding p value was at or below .008.
Years since Graduation
First, a logistic regression assessed whether years since graduation predicted NIA
use. The use of NIA was coded as 0 = No and 1 = Yes. The results of the logistic
regression did not show a significant model, χ2(1) = 0.51, p = .475, Nagelkerke R2 = .02.
This suggests that years since graduation did not predict NIA use. Table 11 presents
results of the logistic regression. These results were replicated using the subset of
participants who were responsible for diagnosing Alzheimer’s disease (χ2(1) = 2.30, p =
.130, Nagelkerke R2 = .16).
Specialty
A logistic regression was conducted to assess if certification “specialty” predicted
NIA use. NIA use was coded as 0 = No and 1 = Yes. The results of the logistic regression
did not show significance in the full model, χ2(1) = 0.15, p = .695, Nagelkerke R2 = .01.
Note: that the individual predictor can have a slightly different p value. This suggests that
certification did not predict NIA use. Table 11 presents results of the logistic regression.
These results were replicated using the subset of participants who were responsible for
diagnosing Alzheimer’s disease (χ2(1) = 0.83, p = .363, Nagelkerke R2 = .06).
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Percent of Patients Over 60
A logistic regression then assessed if the percent of patients older than 60
predicted the use of NIA criteria. NIA use was coded as 0 = No and 1 = Yes. The results
of the logistic regression did not show a significant model, χ2(1) = 1.86, p = .173,
Nagelkerke R2 = .06. Note: that the individual predictor can have a slightly different p
value. This suggests that the percent of patients older than 60 did not predict NIA use.
Table 11 presents results of the logistic regression. These results were replicated using
the subset of participants who were responsible for diagnosing Alzheimer’s disease (χ2(1)
= 0.47, p = .492, Nagelkerke R2 = .03).
Gender
The following logistic regression assessed if gender predicted NIA use. NIA use
was coded as 0 = No and 1 = Yes. Since gender was a nominal variable, it was dummycoded to have female as the reference category. The results of the logistic regression did
not show a significant model, χ2(1) = 0.04, p = .839, Nagelkerke R2 = .00. This suggests
that gender did not predict NIA use. Table 11 presents results of the logistic regression.
These results were replicated using the subset of participants who were responsible for
diagnosing Alzheimer’s disease (χ2(1) = 2.54, p = .112, Nagelkerke R2 = .17).
Age
Next, a logistic regression assessed if age predicted NIA use. NIA use was coded
as 0 = No and 1 = Yes. The results of the logistic regression did not show a significant
model, χ2(1) = 0.67, p = .414, Nagelkerke R2 = .02. This suggests that age did not predict
NIA use. Table 11 presents results of the logistic regression. These results were
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replicated using the subset of participants who were responsible for diagnosing
Alzheimer’s disease (χ2(1) = 1.63, p = .201, Nagelkerke R2 = .12).
Knowledge
The final logistic regression for Research Question 1 assessed if knowledge
predicted NIA use. NIA use was coded as 0 = No and 1 = Yes. The results of the logistic
regression did not show a significant model, χ2(1) = 2.53, p = .112, Nagelkerke R2 = .08.
This suggests that knowledge of Alzheimer’s did not predict the use of NIA criteria.
Table 11 presents results of the logistic regression.
This analysis was then conducted using the subset of participants who were
responsible for diagnosing Alzheimer’s disease. Results of this analysis suggested a
significant relationship between knowledge of Alzheimer’s, and the use of NIA criteria to
diagnose Alzheimer’s (χ2(1) = 7.97, p = .005, Nagelkerke R2 = .47). The results suggested
that approximately 47% of the variance in whether these participants used NIA criteria
was accounted for by differences in their Knowledge of Alzheimer’s. However,
assessment of the individual predictor (knowledge) using the Wald statistic did not
suggest that knowledge was significantly predictive of NIA use (Wald z = 3.64, p = .056).
However, these findings are possibly due to the low sample size.
Table 11
Results for each Logistic Regression Predicting NIA Use
Source

B

SE

z

0.02

0.03

0.71

p

OR

95% CI for
OR

.477 1.02

[0.97, 1.07]

Hypothesis A
Years Since Graduating
Hypothesis B

112
Certified (ref: not certified)
0.32 0.80 0.40 .692 1.37 [1.09, 1.44]
Hypothesis C
Patients older than 60 under care
0.02 0.01 1.37 .171 1.02 [0.99, 1.05]
of respondent
Hypothesis D
Male (ref: female)
-0.16 0.79 -0.20 .840 0.85
Hypothesis E
Age
0.02 0.03 0.81 .417 1.02 [0.97, 1.08]
Hypothesis F
Knowledge
-0.21 0.13 -1.60 .110 0.81 [0.63, 1.05]
Note. Due to the high standard error, the 95% confidence interval could not be computed
for gender.
Research Question 2
Are a physician’s background characteristics and knowledge associated with the
physician’s intention to use the National Institute on Aging (NIA) criteria for the
detection of Alzheimer’s disease (AD)?
To examine the relationship between background characteristics and the use of
NIA criteria for the detection of Alzheimer’s disease, six simple logistic regressions were
first assessed through hypothesis testing. The resulting hypotheses were:
Subquestion 2A: Is the number of years since a physician graduated from medical
school associated with that physician’s intention to use the NIA criteria for the
detection of AD?
H02A: The number of years since a physician graduated from medical
school is not associated with that physician’s intention to use the NIA
criteria for the detection of AD.
Ha2A: The number of years since a physician graduated from medical
school is associated with that physician’s intention to use the NIA criteria
for the detection of AD.
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Subquestion 2B: Is a physician’s area of specialty associated with that physician’s
intention to use the NIA criteria for the detection of AD?
H02B: A physician’s area of specialty is not associated with that
physician’s intention to use the NIA criteria for the detection of AD.
Ha2B: A physician’s area of specialty is associated with that physician’s
intention to use the NIA criteria for the detection of AD.
Subquestion 2C: Is the percentage of patients older than 60 in a physician’s
practice associated with that physician’s intention to use the NIA criteria for the
detection of AD?
H02C: The percentage of patients older than 60 in a physician’s practice is
not associated with that physician’s intention to use the NIA criteria for
the detection of AD.
Ha2C: The percentage of patients older than 60 in a physician’s practice is
associated with that physician’s intention to use the NIA criteria for the
detection of AD.
Subquestion 2D: Is a physician’s gender associated with that physician’s intention
to use the NIA criteria for the detection of AD?
H02D: A physician’s gender is not associated with that physician’s
intention to use the NIA criteria for the detection of AD.
Ha2D: A physician’s gender is associated with that physician’s intention to
use the NIA criteria for the detection of AD.
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Subquestion 2E: Is a physician’s age associated with that physician’s intention to
use the NIA criteria for the detection of AD?
H02E: A physician’s age is not associated with that physician’s intention
to use the NIA criteria for the detection of AD.
Ha2E: A physician’s age is associated with that physician’s intention to
use the NIA criteria for the detection of AD.
Subquestion 2F: Is a physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, associated with that
physician’s intention to use the NIA criteria for the detection of AD?
H02F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is not
associated with that physician’s intention to use the NIA criteria for the
detection of AD.
Ha2F: A physician’s knowledge about AD, as indicated by his or her
performance on the Alzheimer’s Disease Knowledge Scale, is associated
with that physician’s intention to use the NIA criteria for the detection of
AD.
Years since Graduation
The first logistic regression assessed if years since graduation predicted Intent.
Intent was coded as 0 = No and 1 = Yes. The results of the logistic regression did not
show a significant model, χ2(1) = 3.17, p = .075, Nagelkerke R2 = .09. This suggests that
years since graduation did not predict Intent. Table 12 presents results of the logistic
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regression. These results were replicated using the subset of participants who were
responsible for diagnosing Alzheimer’s disease (χ2(1) = 0.47, p = .495, Nagelkerke R2 =
.04).
Certification
A logistic regression then assessed if certification predicted Intent. Intent was
coded as 0 = No and 1 = Yes. Since certification was a nominal variable, it was dummycoded to have NO as the reference category (i.e., Yes = 1, No = 0). The results of the
logistic regression did not show a significant model, χ2(1) = 0.13, p = .724, Nagelkerke
R2 = .00. This suggests that certification did not predict Intent. Table 12 presents results
of the logistic regression. These results were replicated using the subset of participants
who were responsible for diagnosing Alzheimer’s disease (χ2(1) = 0.22, p = .641,
Nagelkerke R2 = .02).
Patients over 60
A logistic regression then assessed if percent of patients older than 60 predicted
Intent. Intent was coded as 0 = No and 1 = Yes. The results of the logistic regression did
not show a significant model, χ2(1) = 0.32, p = .572, Nagelkerke R2 = .01. This suggests
that the percent of patients older than 60 did not predict Intent. Table 12 presents results
of the logistic regression. These results were replicated using the subset of participants
who were responsible for diagnosing Alzheimer’s disease (χ2(1) = 0.00, p = .966,
Nagelkerke R2 = .00).
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Gender
The next binary logistic regression assessed if gender predicted Intent. Intent was
coded as 0 = No and 1 = Yes. Since gender was a nominal variable, it was dummy-coded
to have female as the reference category. The results of the logistic regression did not
show a significant model, χ2(1) = 1.82, p = .178, Nagelkerke R2 = .05. This suggests that
gender did not predict Intent. Table 12 presents results of the logistic regression. This
analysis was then conducted using the subset of participants who were responsible for
diagnosing Alzheimer’s disease (χ2(1) = 4.97, p = .026, Nagelkerke R2 = .35), which did
not indicate any relationship at the Bonferroni corrected alpha level of .008.
Age
A logistic regression next assessed if age predicted Intent. Intent was coded as 0 =
No and 1 = Yes. The results of the logistic regression did not show a significant model,
χ2(1) = 0.02, p = .894, Nagelkerke R2 = .00. This suggests that age did not predict Intent.
Table 20 presents results of the logistic regression. These results were replicated using
the subset of participants who were responsible for diagnosing Alzheimer’s disease (χ2(1)
= 0.25, p = .618, Nagelkerke R2 = .02).
Knowledge
The final logistic regression assessed if knowledge of Alzheimer’s predicted
Intent. Intent was coded as 0 = No and 1 = Yes. The results of the logistic regression did
not show a significant model, χ2(1) = 0.06, p = .800, Nagelkerke R2 = .00. This suggests
that knowledge did not predict Intent. Table 12 presents results of the logistic regression.
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These results were replicated using the subset of participants who were responsible for
diagnosing Alzheimer’s disease (χ2(1) = 0.35, p = .556, Nagelkerke R2 = .03).
Table 12
Results for Each Logistic Regression Predicting Intent
Source

B

SE

z

p

OR

95% CI for
OR

Hypothesis A
Years Since Grad
-0.03 0.02 -1.71 .087 0.97
[0.93, 1.00]
Hypothesis B
Certified (ref: not certified)
0.22
0.63 0.35 .724 1.25
Hypothesis C
Patients Older than 60 under
0.01
0.01 0.56 .573 1.01
[0.99, 1.03]
care of respondent
Hypothesis D
Male (ref: female)
0.78
0.58 1.34 .181 2.18
Hypothesis E
Age
-0.00 0.02 -0.13 .894 1.00
[0.96, 1.04]
Hypothesis F
Knowledge
0.03
0.10 0.25 .800 1.03
[0.84, 1.25]
Note. Due to the high standard error, the 95% confidence interval could not be computed
for certification or gender.
Summary
A complete analysis of the data provided over the course of six months was
conducted as described in Chapter 3 first using a correlational and a bivariate analysis
statistic to assess the data for possible correlation. Consequently, further analysis was
conducted evaluating the data for possible bivariate and multivariate correlations. There
was no statistical correlation using a multivariate analysis and determined no further
reporting was indicated. My next step was to apply a Bonferroni correction as discussed
in Chapters 3 and 4. I applied the Bonferroni correction for the original .05 alpha. The
modeling was unable to provide enough statistical sensitivity to identify one or more
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statistical correlations between physicians’ background characteristics/AD knowledge
and their use of and intention to use the NIA criteria. I will discuss my interpretation of
the findings next in Chapter 5.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Clinicians rely on a patient’s history and physical examination when formulating
their diagnoses. Clinicians often do not diagnose dementia during patient visits and
approximately half of the patients with dementia symptoms ranging from mild to
moderate have never received diagnosis of dementia or Alzheimer’s disease (AD) from a
clinician (USPSTF; as cited in Boustani, Peterson, Harris, & Lohr, 2003). Primary care
clinicians need a screening test with measurable outcomes when constructing their patient
diagnosis and treatment plans, one that could be used during a single office visit and
correlated to the DSM-IV-TR (Boustani et al., 2003).
Still, a recent study recommends three such in office test for the early diagnosis of
AD leading toward other AD tests such as the Clock Draw test (CDT, Jack et al., 2011).
In office tests such as the Mini-Cog uses the components of the MMSE that include
specifically the three-item recall, testing the person for the ability to recall three words
after roughly 1 minute, and a CDT (Kamenski et al., 2009). Jack et al., (2011) identified a
four-item recall test. Primary care clinicians need a screening test with measurable
outcomes, which could be used during a single office encounter and correlated to the
DSM-IV-TR (Boustani et al., 2003).
According to estimates (Christensen & Lin, 2007), there are over 5 million
diagnosed cases of AD in the United States and that number could reach or
exceed 15 million by 2050 according to studies indicating AD may be
underreported for the actual numbers of reported cases of AD (Christensen & Lin,
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2007). Furthermore, because AD may be underreported AD can be diagnosed in
the early stages of the disease within the primary care setting (Christensen & Lin,
2007 and Fearing et al. 2007). Additionally, the rates of AD diagnoses will
increase annually as the elderly population in the United States increases
(Christensen & Lin, 2007). Lindesay et al. (2010) reported that physicians still
use the word senile dementia when diagnosing a patient with AD-type dementia.
However, the current literature states that, to make an accurate diagnosis, an
autopsy must be performed and brain tissue examined under a microscope
(Christensen & Lin, 2007). In summary, because AD may go underreported, may
be misdiagnosed, and is not clearly defined as seen in the DSM-IV-TR then
additional research to choreograph medical terminology associated with the
diagnostic term “AD”.
In this study I sought to understand how many physicians are aware of the new
NIA criteria and if they intend to use them in the future. I further examined physicians
patterns of use of the new NIA AD criteria. What is still lacking is consensus on the exact
symptoms of AD that GPs can use to diagnose early-, middle-, and late-stage AD in their
patients. No studies have been conducted exploring physicians use or willingness to use
the new NIA AD criteria (Jack et al., 2011).
The demographics used in this study did not result in one or more demographic
being statistically sensitive enough to predict which might predict future use of the new
NIA criteria. The lack of respondents and completed surveys affected my ability to
conduct a multivariate analysis as discussed in Chapter 3 and the overall results of my
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survey despite tireless efforts to achieve the minimum sample size. Specific
demographics such as the number of years since graduating from medical school, area of
specialty, percentage of patients over age 60 years, physician gender, physician age, and
knowledge about AD, as indicated by performance on the ADKS were examined. The
framework for this chapter includes a discussion of the interpretation of the findings,
limitations of the study, recommendations for action, implications for social change, and
ends with the chapter conclusion. The purpose of this research investigated physician use
of the NIA AD protocol through a series of two primary research questions concerning
the relationship between various physician background characteristics and use of and
intention to use the NIA criteria for all-cause dementia and the early detection of
Alzheimer’s disease. Next, I will present my interpretation of the findings.
Interpretation of the Findings
My interpretation of the key findings is presented with caution due to the limited
sample size being reported because the findings did not reach the minimum required for
any of the analyses to be statistically significant for a multivariate analysis. The results
were sound for a correlational and a bivariate analysis. The following discussion
represents my interpretation of my findings.
My statistical analysis indicated there are no independent indicators clearly
predicting if or when a physician will or will not use the NIA diagnostic criteria for
diagnosing a patient with AD. Likewise, the U.S. Preventive Services Task Force
(USPSTF; as cited in Boustani, Peterson, Harris, & Lohr, 2003) reported insufficient data
for offering a conclusive recommendation either for or against routinely screening
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patients, aged 65 and over, with dementia symptoms. When examined separately none of
the six (A-F) hypothesized factors were related to the use of NIA criteria to diagnose
Alzheimer’s disease. The six analyzed factors included years since graduation,
certification, percent of patients older than 60, gender, age, and knowledge about
Alzheimer’s disease. The results for each bivariate analysis were not significant at the α =
.05 level, or at the Bonferroni corrected level of α = .008. As such, none of the analyses
could be used to describe the strength or direction of bivariate relationships between any
factor and the use of NIA criteria. The results from Chapter 4 confirms previous research
presented in Chapter 4 in that no one variable or combination of multivariables presented
a model to predict the use of the new NIA AD diagnostic protocol criteria. Additionally,
the small sample size greatly reduced the possibility of finding associations, which may
have been found in a multivariate environment if indeed there were some associations.
My descriptive findings demonstrated that the average score on the ADKS was
about 20–30 questions correct and that there was a wide range of scores. Also, when
examined separately, none of the six hypothesized factors were related to the intention to
use of NIA criteria to diagnose Alzheimer’s disease or, relatedly, the intention to not use
NIA criteria. The six analyzed factors included years since graduation, certification,
percent of patients older than 60, gender, age, and knowledge about Alzheimer’s disease.
The results for each bivariate analysis were not significant at the α = .05 level, or at the
Bonferroni corrected level of α = .008. As such, none of the analyses could be used to
describe the strength or direction of bivariate relationships between any factor and the
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intent to use of NIA criteria in the future confirming the published literature, i.e.,
(USPSTF; as cited in Boustani, Peterson, Harris, & Lohr, 2003).
I examined all variables simultaneously. The goal of these analyses was to
determine if the full set of factors was able to significantly predict the use, or intent to use
NIA criteria. Though each variable was assessed independently, the inclusion of multiple
variables typically contributes to increased predictive ability in a regression model
(Pallant, 2010). As such, one model was conducted for each dependent variable (i.e., use
of NIA criteria and intention to use NIA criteria). Intention to use the NIA criteria was
assessed to examine RQ2,the intention to use.
I calculated my statistical analysis using a binary logistic regression model to
predict significan trelationships within the data collected from my survey instrument then
univariate to predict significant relationships within the data collected from my survey
instrument. Results from the univariate model and binary logistic regressions did not
indicate any significant relationship between the factors of interest and either the use of
NIA critieria or the intention to use NIA critiera. When I further evaluated the data using
a univariate model the data were non-significant at both the critical alpha of α = .05.
When I applied the Bonferroni adjustment setting the alpha, α = .008, my results
indicated the number of years since graduation, certification, percentage of patients older
than 60, gender, age, and knowledge of Alzheimer’s disease were not significant
predictors. I used critial alpha of α = .05 and also applied the Bonferroni correction alpha
of α = .008 when I interpreted the results from the models. The statisical models
demonstrated no significant associations and no predictive relationships were found at
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these levels in that the variables were non-significant for further interpretation and
possible predictions.
Limitations of the Study
Results of this study should be interpreted with caution. Traditional caution for a
binary logistc regression suggests that for each predictor variable, the sample should
include responses from at least 10 participants with “yes” responses to the dependent
variable, and 10 participants with “no” responses. For each simple binary logistic
regression, only approximately 20 participants were necessary as a minimum, however,
for the larger models in the multivariate analyses, up to 120 participants may have been
necessary to determine statistical significance (Peduzzi et al., 1996). Other suggestions
for sample size requirements, even those for simple binary regression, suggest up to 300
participants minimally (Hsieh, Block, & Larsen, 1998). The statistical models presented
in Chapter 3 indicated a G*Power sample size of 97 was needed for a multivariate
analysis and my final collection of survey respondants would have been 97 or greater. As
discussed in previous chapters, a multivariate was not statistically supported with ony 89
respondents. However, a Priori Power analysis was conducted and indicated a total
sample size of 16 was required and 89 surveys were collected. After cleaning the data I
removed 34 surveys the sample size. The 34 surveys were removed because they were
not healthcare providers or did not provide completed surveys. My critieria for what
constituted a completed survey filtered to ensure the respondent was a healthcare
provider such as either a doctor or nurse and answered all of the survey questions. As
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such, the reporting sample size of 55 participants may have been insufficient to determine
significance where it did exist.
A clear limitation of this survey was that respondents did not clearly indicate they
were a physican, indicate they were board certified and if so which board they had
passed, or nurse and if a nurse what level of nursing degree they held, i.e., LPN, RN, or
Nurse Practionier and of those 20 repondents they did not complete the entire survey. My
survey was designed with filters to prescreen respondents at the onset of the survey based
upon initial repsonses. For example, if a respondent answered they were a technician or
administrator by profession they were automatically disqualified and exited the survey.
However, if the respondent indicated they were either a physician or nurse by profession
the online survey automatically advanced them to the next question. A better designed
survey may have captured the actual number of actual physicians, type of physicians/area
of practice, certification, and or specialty and or specific number of nurses indicating
their specific nursing license/area of practice. This question had 17 positive responses.
One respondent indicated she/he was a gerontologist, another optomitrist, and others
were nurse practionioners.
However, one question within the survey did ask about one’s advanced training,
are you board certified and if so please indicate by writing in your response. Additionally,
each of the demographic questions and subsequent questions allowed the respondent to
“fill-in” or indicated an area for additional write in responses. Another limitation of the
study involved external validity due to the utilization of a convenience, or non-random
sample technique. A convenience sampling strategy was selected for this research.
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Convenience sampling was selected because the sample was taken from one geographic
area (two northern California counties). I am aware that findings from this study may not
be applicable to other physicians in California, in other states and localities, as
demographic factors may skew data in some unknown manner, however, I intentionally
selected my six variables as they were supported by the literature review from studies
presented in Chapter 2.
Recommendations for Action
An interesting outcome observed in Table 11 found in Chapter 4 regarding
knowledge of AD—hypothesis F approached significance. The beta of (-0.21) predicts
the opposite of the p value. In other words as the p value increases by one so should the
beta—this is an anomaly requiring further research. This is interpreted as knowledge of
AD increases the intent of using the New NIA AD diagnostic criteria decreases even after
a Bonferroni corrected level of α = .008 and counter intuitive. Furthermore, this
discovery may correlate to the actual number of doctors and nurses completing my
survey. My recommendation for future research is to examine this potential predictor in
greater detail.
The results of my study advances the current knowledge for future studies
examining which factors may influence the use of new diagnostic tools for diagnosing
patients with early symptoms of AD and the implementation of the NIA AD criteria.
Despite the limitations of a low response rate, new information is valuable for future
researchers in that this study provides important and initial ground work for continued
research. As mentioned in earlier chapters, no other research to date examined the
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potential criteria which may predict physicians intention to use or not to use new
diagnostic criterion for the early diagnosis of AD.
I advocate the following modifications for future researchers exploring the same
topics as I. I would first address the need for increasing and obtaining more respondants
to the survey instrument. I sought out several key personnel and for one reason or another
they backed out. My recommendation is to work with key personnel that advocate the
need for continuing research to advance knowledge on the three research questions
presented herein. One might seek out multiple key advocates from three to five counties
with similar demographics. Additionally, one might consider using a paper survey versus
an online survey following a presentation on a topic such as new criteria for diagnosing
AD. A pre-test and post test could successfully evaluate pre and post knowledge,
attitudes, and behaviors for patients with AD and those attitudes and behaviors for
paitents with AD. I would also revise the title of my survey to sound more inclusive of a
wide range of eligible healthcare providers and remove the wording gerontoligist.
Additionally, I would refine my demographic questions at the onset of the survey to
inquire more detials about respondent’s level of training, certification, and speciality
degrees/boards.
Because there was such a low response rate to my survey instrument I would
recommend future researchers continue this initial work to seek out which if any
predictors can successfully predict when physicians’ will or will not use the NIA
diagnostic criteria. As continued research comes closer to discovering the etiology of AD
one might presume therefore a diagnostic tool or tests will parallel the same discovery. I
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would further recommend continued training on current diagnostic methodologies in the
form of continuing education and in-service training. For example, a pretest on the
subject of diagnostic criteria could be distributed to a group of attendees. The pretest
could then be collected followed by a presentation regarding NIA diagnostic criteria for
diagnosing AD. Following the presentation, one could then reassess the attendees and
evaluate newfound knowledge, change in attitudes regarding AD, and evaluate a change
in behaviors toward the new diagnostic criteria (Wright et al., 2011).
Additional research is recommended using the same survey instrument herein and
build upon my findings to continually advance the discoveries elucidated. Additionally,
future studies should strive for an increased sample size for greater statistical power
analysis. Data from a larger respondent pool may provide clear evidence with which to
predict physicians’ knowledge, attitudes, and behaviors about AD criteria. While there is
limited data from my study regarding providers knowledge, attitudes, and beheaviors of
AD I would suggest one could possibly develop an intervention program involving a
pretest, training on AD diagnostic criteria, and post test to assess learning outcomes
(Davis, et al., 1999). The learning outcomes could then be assessed and matched with a
training program and potentially linked to a policy and/or procedure implementing new
AD diagnostic criteria. I would also recommend the use of Roger’s diffusion of
innovation theory to implement a change in policy and/or procedures within an
organization. Rogers’s (2003) diffusion of innovations (DOI) theory is appropriate to use
for implementing change in knowledge. As previously recommended, a partnership with
the NIA reference materials and a robust training program Roger’s DOI model is
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recommended for closing the gap in AD knowledge within an organization as discussed
in Chapter 2.
I further recommend a study expanding the new knowledge herein to evaluate the
source documents used by healthcare providers when making a diagnosis of AD. For
example, exploration of physicians use of desktop references, training in medical school,
specialty training, and or use of the International Classification of Diseases (ICD) and
DSM-IV-TR is recommended. The use of the diagnostic term senile dementia used in the
DSM IV falsely promotes the notion that dementia naturally occurs as one ages. Boustani
et al. (2003), reported the many benefits of early detection of AD within a physicians’
office and that following an interview and clinical examination by a physician could be
accomplished within the guidelines of the DSM-IV-TR There is an established
partnership with the NIA and the Alzheimer’s Association, which published new criteria
for diagnosing patients with dementia of the AD type symptoms almost 30 years ago.
Additionally, respondents to my survey instrument are not fully aware of the new NIA
AD protocols and updates. In addition, none of my respondents indicated which if any
protocols they followed for making a diagnosis of AD and a topic for future researchers
to explore. I reported in Table 7, 36% of my respondents were responsible for making an
AD diagnosis and were unaware of the new NIA criteria.
What may be lacking is an alignment or collaboration between the current
version/edition of the ICD, use of the current version/edition of the DSM, which
physicians may reference to diagnose patients with AD and consistent guidelines for
physicians to reference in their assessment of AD symptoms as discussed in Chapter 2. I
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recommend an alignment between ICD, DSM, and NIA align terminology, definitions,
and codes found in both the ICD and DSM with a future study to discover additional
associations, benefits, and or correlations especially regarding AD.
Implications for Social Change
The key findings and recommendations for action presented here may have
significant implications for social change. Healthcare providers need more training
regarding AD symptoms, presentation of signs of AD, and earlier diagnosis to improve
the diminishing lifespan of those afflicted with this deadly disease. , As presented in
Chapter 2 and from the recommendation discussed in recommendations for Key Finding
3, physicians and the healthcare community at large need to develop consistent
terminology for the various types of dementia and dementia of AD.
As such, the medical community could benefit from aligning their desktop
reference and terminology to accurately describe, code, and reference AD. An alignment
or collaboration is highly recommended between the current version/edition of the ICD
and the current version/edition of the DSM, which physicians reference to diagnose
patients with AD. The passé use of the diagnostic term senile dementia as used in the
current edition DSM IV falsely promotes the notion that dementia naturally occurs as one
ages and both the ICD and DSM should parallel one another. I developed the acronym
Classic Alzheimer’s Disease Symptoms (CADS) and defined CADS in Chapter 2 as a
way to refer to patients with dementia of the AD type. The social change and potential
implication may advance the use of diagnostic phrase, “Classic Alzheimer’s Disease
Symptoms (CADS),” rather than labeling patients with the term “Alzheimer’s Disease”
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or even “being senile.” Rather than labeling a living patient with AD, I would
recommend referring to living patients with dementia of the AD type as having (CADS).
Until the healthcare sector has a biomarker and begins early testing for signs and
symptoms of AD as recommended by the NIA and Alzheimer’s Association, we will
continue to see misdiagnosed patients and under reporting of AD (USPSTF; as cited in
Boustani, Peterson, Harris, & Lohr, 2003). Furthermore, close coordination with the
World Health Organization, DSM, and ICD is needed to unite physician desktop
references such as the DSM and ICD also used by both insurance companies in the
United States and billing coding specialists to complete insurance claims for patient
treatment; currently a gap exists as identified and discussed in Chapter 2.
Significance
The U.S. National Institute on Aging ranked AD as the sixth most deadly disease
Alzheimer’s Association (2012a). The benefits of early detection and accurate diagnosis
of AD, like many other diseases, include disease management and improved quality of
life. An accurate and early diagnosis may also decrease stress for those seeking a reason
for loved ones’ sudden changes in personality, mood, activities, and behavior. An early
diagnosis of AD may thus help ease tensions within a family.
My study may lead to social change by promoting awareness of the importance
for early AD diagnosis and the use of new diagnostic guidelines and materials such as the
NIA criteria. Accurate diagnosis may assist families in reviewing finances, legal
planning, discussing home and long-term care alternatives, and evaluating safety
practices (Leifer, 2009). This study may promote social change by encouraging providers
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to implement routine procedures for the detection of possible dementia in primary care
patients during office and clinic visits. Additionally, this study may illuminate the needs
and benefits for early diagnostic evaluations for persons suspected of exhibiting AD
symptoms, partner with those who are likeminded to provide care planning at the earliest
possible time following a diagnosis, and document the diagnosis and care plan in a
person’s medical record (Attea & Johns, 2010).
Conclusion
Patients and/or family members caring for a loved one with CADS may initially
seek help from their primary care physicians (PCPs) (Leifer, 2009). At this time, there is
no cure or known cause for AD. Furthermore, AD cannot be used as a diagnosis for the
living because there is no definitive diagnostic biomarker. Currently, after a patient dies
when an autopsy is performed to examine brain tissue and during the autopsy, the results
of the autopsy are conclusively used describing the cause of death due to AD or other
causes (Christensen & Lin, 2007). Okie (2011) reported that some physicians and
agencies avoid using a diagnosis of AD. An accord is lacking regarding early diagnostic
criteria and the exact symptoms of Alzheimer’s disease that physicians’ use to diagnose
AD patients. In the last three years, Jack et al. (2011) co-authored a study with the
Alzheimer’s Association, which undertook significant efforts to revise previous
diagnostic criteria for physicians’ to use when evaluating patients with dementia type
AD. An in office test may help physicians detect the early symptoms of AD based upon
new National Institute of Aging criteria. Therefore, it is important for PCPs to be familiar
with and to employ consistent diagnostic approaches and nomenclature.
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My study explored the patterns of use related to the new National Institute of
Aging Alzheimer’s disease protocol was conducted because no other researcher to date
has explored this area. The findings support the need to improve primary care providers’
initial diagnostic skills for evaluating dementia/AD patients including the use of the new
NIA criteria. I encourage future researchers to conduct a qualitative study to explore why
the clinicians do not intend to use the NIA criteria and to learn what it will take to get
clinicians to adopt the new NIA AD criteria. I greatly hope my findings advance the
current knowledge and understanding of Alzheimer’s disease. At the very least, I hope I
have inspired future researchers to pick up where I left off.
In summary, doctors can benefit from additional AD knowledge training, using a
standardized in office test to screen patients with AD symptoms, and routine diagnostic
criteria from the NIA is available for doctors to reference for all stages of AD in an
overarching goal for earlier detection of Alzheimer's disease and treatment of AD. Until a
cure for AD is discovered earlier, detection of AD symptoms is indicated and early
treatment for the early signs of AD and/or CADS may extend patients’ quality of life.
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Appendix B: Alzheimer’s Disease Survey
Introduction
Hello and thank you for volunteering about 15 – 20 minutes to complete
the survey. You were selected as a potential participant in this study because you
are thought to be involved in direct care and work with patients diagnosed with
dementia. This study is being conducted by a researcher named Richard Schultz,
who is a doctoral student at Walden University.
Instructions: This is an online survey. The survey will take you though a
pre-qualification process to ensure the survey instrument itself is accessed by
appropriate healthcare providers. Please read the instructions carefully for each
section. Please proceed.
Please click “Next” to continue or click on “exit” to leave the survey and
return later.
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Alzheimer’s Disease Survey Pre-qualification Questions
Instructions: Congratulations and welcome to the pre-qualification
questions. There are three questions that will screen for appropriate respondents to
this survey. The survey will take you though a pre-qualification process to ensure
the survey instrument itself is accessed by appropriate healthcare providers.
Please read the instructions carefully for each section. Please answer the
following three questions.
1. What is your role within the healthcare system?
a. __Physician
b. __Nurse
c. __Technician
d. __Administrator
e. __Other, please describe
2. In your role within the healthcare system are you medically and legally
responsible for diagnosing a person with Alzheimer’s disease?
a. __Yes
b. __No
3. Which county do you predominantly practice?
a. __Tuolumne County
b. __Stanislaus County
c. __Sonoma County
d. __Sacramento County
*Note: If the respondent replied b, c, d, or e to question #1 then the
respondent does not meet the criteria to continue and is taken to the end of
the survey and thanked for their time.
*Note: if the respondent replied b to question #2 then the respondent is not
qualified to continue and is taken to the end of the survey and thanked for
their time.
*Note: if the respondent replied a, c, or d to question #3 then the respondent
is not qualified to continue and is taken to the end of the survey and thanked
for their time.
Please click “Next” to continue or click on “exit” to leave the survey and return
later.
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Survey Pre-qualification Ineligible Page
Thank you for answering the survey pre-qualification questions. Unfortunately,
you do not meet the selected criteria necessary to continue with the remaining survey
questions. We appreciate your time and continued dedication to Alzheimer’s patients,
their families, and caregivers.
Instructions: Although you do not meet the criteria to proceed with the
rest of the survey, we ask you to click on the hyperlink below to learn more about
Alzheimer’s disease, new criteria released by the National Institute of Aging, and
their additional recommendations. Please visit the following website:
http://www.alz.org/documents_custom/Alz_Assoc_diag_criteria_guidelines_press
_release_041911.pdf

Only if the respondent chose response “A” in question #1, responded “A” to
question #2, and responded “B” to question #3 then the surveyor may
proceed to the Survey Consent Form.
Please click “Next” to continue or click on “exit” to leave the survey and
return later.
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Alzheimer’s Disease Survey Consent Form
Congratulations! You successfully qualified to complete the Alzheimer’s
Disease Survey. Based on your answers to the previous three questions you are
ready to start the survey. But first, you will need to familiarize yourself with the
following consent form.
You were selected as a potential participant in this study because you are a
direct care staff working with patients diagnosed with dementia. Please read this
form and ask any questions you have before agreeing to be part of the study. This
study is being conducted by a researcher named Richard Schultz, who is a
doctoral student at Walden University.
Instructions: Congratulations and welcome to the consent form. Please
read the consent form to continue and please fill in and complete all responses to
the following fields. After completing the consent form, please click the “next”
button to precede indicating you have read and consent to the terms of this survey.
Background Information:
The purpose of this study investigates what effect Physicians Knowledge,
Attitudes and Utilization Patterns are in relationship to the new National Institute
of Aging Criteria for all-cause dementia: Early detection of Alzheimer’s disease.
Procedures:
If you agree to be in this study, you will be asked to:
• Sign and return this form directly to the researcher
• Complete a short demographic form, followed by a survey.
• The survey is the Alzheimer’s Disease Knowledge Scale, consisting of 30
items.
o Voluntary Nature of the Study: Your participation in this study is
voluntary. This means that everyone will respect your decision of
whether or not you want to be in the study. If you decide to join the
study now, you can still change your mind later. If you feel stressed
during the study you may stop at any time. You may skip any
questions that you feel are too personal.
o Risks and Benefits of Being in the Study: There are no physical risks
and no benefits to participating in the study. Should there be any
emotional upset while completing the surveys, participants can stop
and decide not to continue with study or come back at a later time to
complete the surveys.
o Compensation: No compensation will be available for participating
in this study.
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o Confidentiality: Any information you provide will be kept
confidential. The researcher will not use your information for any
purposes outside of this research project. Also, the researcher will not
include your name or anything else that could identify you in any
reports of the study.
o Contacts and Questions: The researcher conducting this study is
Richard Schultz. The researcher’s faculty advisor is Dr. Richard
Jimenez. You may ask any questions you have now. Or if you have
questions later, you may contact the researcher at
Richard.Schultzjr@waldenu.edu or the advisor at
Richard.Jimenez@waldenu.edu.
The researcher will email and/or you may download a copy of this form to keep.
Statement of Consent:
I have read the above information. I have received answers to any questions I
have at this time. I am 18 years of age or older, and I consent to participate in the
study.
Printed Name of Participant _________________________________________
Participant’s Written Signature

___________________________________

Researcher’s Written Signature

___________________________________

Note: The respondent cannot continue unless the consent form has been
reviewed (indicated by clicking on a radio button) indicating acceptance and
completion allowing the participant to proceed.
Please click “Next” to continue or click on “exit” to leave the survey
and return later.
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Part one is comprised of 8 background and demographic questions.
Part two is comprised of 30 brief questions (True and False), which ask
specific knowledge questions about Alzheimer’s disease and pose various
statements. It’s important to indicate an answer for every statement, even if you’re
not completely sure of the answer.
Instructions: Congratulations and welcome to the Background and
Demographic Information portion of the survey. Please read each question and
either fill in the answer or select the appropriate response from the choices below.
After completing this section, please click the “next” button to proceed indicating
you are ready to continue to the next section of the survey.
Background Questions and Demographic Information (Part 1)
1. How old were you on your last birthday (please write in):_____________.
2. What is your gender?
a. __Male
b. __Female
c. __Other, please write in:________________________________.
3. How many years ago did you graduate from medical school? (please write
in)_________.
4. Are you board certified? If so, in which specialty are you certified?
a. __Yes, (please write in):________________________________.
b. __No
5. Do you use the new National Institute of Aging protocol for early
diagnosing Alzheimer’s patients?
a. __Yes
b. __No
c. __Other: (please write in):____________________________________.
6. If you do not use the National Institute of Aging protocol for early
diagnosing of Alzheimer’s patient’s will you use the new protocol in the
next 12 months?
a. __Yes
b. __No
c. __Other (please write in):_____________________________________.
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7. If you do not intend to use the new NIA AD protocol, are you aware of the
new National Institute of Aging protocol for early diagnosing Alzheimer’s
disease?
a. __Yes
b. __No
c. __Other:______________________________________________.
8. What is the percentage of patients aged 60 and older presently under your
care?
a. __20%
b. __30%
c. __40%
d. __50%
e. __Other:____________________________________________.

Please proceed and complete (Part 2).

Please click “Next” to continue or click on “exit” to leave the survey and
return later.
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Alzheimer’s Disease Knowledge Scale (Part 2)
Instructions: Congratulations and welcome to the Alzheimer’s Disease
Knowledge Scale portion of the survey. Below are 30 statements about
Alzheimer’s disease. Please read each statement carefully and indicate whether
you think the statement is true or false. If you aren’t sure of the right answer,
make your best guess. It’s important to indicate an answer for every statement,
even if you’re not completely sure of the answer. After completing this section,
please click the “next” button to proceed indicating you are ready to continue to
the next section of the survey.
1. True/False. People with Alzheimer’s disease are particularly prone to
depression.
2. True/False. It has been scientifically proven that mental exercise can prevent
a person from getting Alzheimer’s disease.
3. True/False. After symptoms of Alzheimer’s disease appear, the average life
expectancy is 6 to 12 years.
4. True/False. When a person with Alzheimer’s disease becomes agitated, a
medical examination might reveal other health problems that caused the
agitation.
5. True/False. People with Alzheimer’s disease do best with simple, instructions
given one step at a time.
6. True/False. When people with Alzheimer’s disease begin to have difficulty
taking care of themselves, caregivers should take over right away.
7. True/False. If a person with Alzheimer’s disease becomes alert and agitated
at night, a good strategy is to try to make sure that the person gets plenty of
physical activity during the day.
8. True/False. In rare cases, people have recovered from Alzheimer’s disease.
9. True/False. People whose Alzheimer’s disease is not yet severe can benefit
from psychotherapy for depression and anxiety.
10. True/False. If trouble with memory and confused thinking appears suddenly,
it is likely due to Alzheimer’s disease.
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11. True/False. Most people with Alzheimer’s disease live in nursing homes.
12. True/False. Poor nutrition can make the symptoms of Alzheimer’s disease
worse.
13. True/False. People in their 30s can have Alzheimer’s disease.
14. True/False. A person with Alzheimer’s disease becomes increasingly likely
to fall down as the disease gets worse.
15. True/False. When people with Alzheimer’s disease repeat the same question
or story several times, it is helpful to remind them that they are repeating
themselves.
16. True/False. Once people have Alzheimer’s disease, they are no longer
capable of making informed decisions about their own care.
17. True/False. Eventually, a person with Alzheimer’s disease will need 24-hour
supervision.
18. True/False. Having high cholesterol may increase a person’s risk of
developing Alzheimer’s disease.
19. True/False. Tremor or shaking of the hands or arms is a common symptom in
people with Alzheimer’s disease.
20. True/False. Symptoms of severe depression can be mistaken for symptoms of
Alzheimer’s disease.
21. True/False. Alzheimer’s disease is one type of dementia.
22. True/False. Trouble handling money or paying bills is a common early
symptom of Alzheimer’s disease.
23. True/False. One symptom that can occur with Alzheimer’s disease is
believing that other people are stealing one’s things.
24. True/False. When a person has Alzheimer’s disease, using reminder notes is
a crutch that can contribute to decline.
25. True/False. Prescription drugs that prevent Alzheimer’s disease are available.
26. True/False. Having high blood pressure may increase a person’s risk of
developing Alzheimer’s disease.
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27. True/False. Genes can only partially account for the development of
Alzheimer’s disease.
28. True/False. It is safe for people with Alzheimer’s disease to drive, as long as
they have a companion in the car at all times.
29. True/False. Alzheimer’s disease cannot be cured.
30. True/False. Most people with Alzheimer’s disease remember recent events
better than things that happened in the past.
Please click “Next” to continue.
Thank you for completing the survey you and you are finished with the
survey
Note: This concludes the survey, which includes both parts 1 and 2. Thank
you for your assistance. If you would like to learn more about Alzheimer’s
disease, new criteria released by the National Institute of Aging, and additional
recommendations, please visit the following website:

http://www.alz.org/documents_custom/Alz_Assoc_diag_criteria_guidelines_press
_release_041911.pdf
Click Here if you would like to have a copy of the Consent Form emailed to you.
Please provide your email address
here:___________________________________
Please confirm your email address
here:___________________________________

156
Appendix C: Certificate of Completion – “Protecting Human Research Participants”

